書籍詳細

炎症リウマチ

P.9 掲載の参考文献

• 1) Rich S. Executive summary from the World Symposium on primary pulmonary hypertension 1998. World Health Organization website. available at:www.who.int/ncd/cvd/pph.html

• 2) 循環器病の診断と治療に関するガイドライン (1999-2000年度合同研究班報告). 肺高血圧症治療ガイドライン. Japanese Circulation Journal 2001;65 Suppl V:1081.

• 3) 西間木友衛. ほか. 混合性結合組織病の肺高血圧症診断の手引き. リウマチ1991;31:159-166.

• 4) 大田恵子, 由谷親夫. PPHの分子病態-最新の知見-(1)病理学的分類. Thrombosis and Circulation 2003; 11:10-15.

• 5) Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Progress in Cardiovascular Diseases 2002;45:225-234.
  pubmed

• 6) Nakagawa N, Osanai S, Ide H, et al. Severe Pulmonary Hypertension associated with primary Sjogren's syndrome. Internal Medicine 2003;42:1248-1252.

• 7) Tanaka E, Harigai M, Tanaka M, et al. Pulmomary hypertension in systemic lupus erythematosus:evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002;29:282-287.

• 8) Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:7681.

• 9) Sitbon O, Humbert M, Ioos V, et al. Who benefits from long-term calcium-channel blocker therapy in primary pulmonary hypertension? Am J Respir Crit Care Med 2003;167:A440. abstract.

• 10) Humbert M, Sitbon O , Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351:1425-1436.
  pubmed

• 11) Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 2000;132:425-434.

• 12) 京谷晋吾. 膠原病性肺高血圧症に対するプロスタサイクリン治療.

• 13) Barst RJ, McCoon M, McLaughlin V, et al. Beraprast therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-2125.

• 14) Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896903.

• 15) Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-1222.
  pubmed

• 16) Kawut SM, Taichman DB , Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-350.
  pubmed

P.18 掲載の参考文献

• 1) Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000;27:1501-1505.

• 2) Park YB, Park YS, Lee SC, et al. Clinical analysis of gouty patients with normouricaemia at diagnosis. Ann Rheum Dis 2003;62:90-92.
  pubmed

• 3) Katz WA, Schubert M. The interaction of monosodium urate with connective tissue components. J Clin Invest 1970;49:1783-1789.
  pubmed

• 4) Terkeltaub RA. Pathogenesis and treatment of crystal-induced inflammation. In:Arthritis and allied conditions, 14th ed, In:Koopman WJ, editor. Philadelphia:Lippincott Williams & Wilkins;1997:2329.

• 5) Wyngaarden JB, Kelley WN. Gout and hyperuricemia. New York:Grune & Stratton;2001.

• 6) http://www.ne.jp/asahi/lapis/fluorite/essay/crystalization.html

• 7) Simkin PA. Synovial physiology. In:Arthritis and allied conditions, 14th ed, In:Koopman WJ, editor. Philadelphia:Lippincott Williams & Wilkins;1997:174

• 8) Weinberger A, Wysenbeck A, Agam G, et al. Synovial fluid urate concentration in normouricemic and hyperuricemic subjects without joint diseases. Clin Chim Acta 1981;111:279-280.
  pubmed

• 9) Edwards JCW. Synovium. In Primer on the rheumatic diseases, 12th ed, In:Klippel JH, editor. Atlanta:Arthritis Foundation;2001:22.

• 10) Yu KH, Intraarticular tophi in a joint without a previous gouty attack. J Rheumatol 2003;30:1868-1870.

• 11) Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991;34:141-145.
  pubmed

• 12) Pascual E, Batlle-Gualda E, Martinez A, et al, Synovial fiuid analysis for diagnosis of intercritical gout. Ann Intern Med 1999;131:756-759.

• 13) Rouault T, Caldwell DS, Holmes EW. Aspiration of the asymptomatic metatarsophalangeal joint in gout patients and hyperuricemic controls. Arthritis Rheum 1982;25:209-212.
  pubmed

• 14) MacCarty DJ. Gout without hyperuricemia. JAMA 1994;26:302-303.

• 15) Sutro CJ. The big toe. Comparative anatomic and radiographic study of the metatarso-phalangeal articulation. Bull Hosp Joint Dis 1965;26:141-174.
  pubmed

• 16) Fam AG, Stein J, Rubenstein J. Gouty arthritis in nodal osteoarthritis. J Rheumatol 1996;23:684-689.
  pubmed

• 17) Wilcox WR, Khalaf AA. Nucleation of monosodium urate crystals. Ann Rheum Dis 1975;34:332-329.
  pubmed

• 18) Simkin PA. The pathogenesis of podagra. Ann Intern Med 1977;86:230-233.
  pubmed

• 19) Schumacher HR. Bullous tophi in gout. Ann Rheum Dis 1977;36:91-93.
  pubmed

• 20) Tak HK, Cooper SM, Wilcox WR. Studies on the nucleation of monosodium urate at 37°C. Arthritis Rheum 1980;23:574-580.

• 21) Kam M, Perl-Treves D, Caspi D, et al. Antibodies against crystals. FASEB 1992;J6:2608-2613.

• 22) Burt HM, Dutt YC. Growth of monosodium urate monohydrate crystals:effect of cartilage and synovial fluid components on in vitro growth rates. Ann Rheum Dis 1986;45:858-864.
  pubmed

• 23) McGill NW, Dieppe PA. The role of serum and synovial fluid components in the promotion of urate crystal formation. J Rheumatol 1991;18:1042-1045.
  pubmed

• 24) McGill NW, Dieppe PA. The effect of biological crystals and human serum on the rate of formation of crystals of monosodium urate monohydrate in vitro. Br J Rheumatol 1991;30:107-111.
  pubmed

• 25) Wollaston S, Brion P, Kumar A, et al. Complications of knee arthroscopy performed by rheumatologists. J Rheumatol 2001;28:1871-1873.
  pubmed

• 26) Gordon TP, Reid C, Rozenbilds MA, et al. Crystal shedding in septic arthritis:case reports and in vivo evidence in an animal model. Aust NZJ Med 1986;16:336-340.

• 27) Doherty M, Dieppe PA. Acute pseudogout:"crystal shedding" or acute crystallization? Arthritis Rheum 1981; 24:954-957.
  pubmed

• 28) 作山理子, 山中 寿, 箱田雅之, ほか. 痛風発作を誘発しないための血清尿酸値の維持水準に関する研究. プリン・ピリミジン代謝1993;17:81-89.

• 29) Becker MA, Schurnacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase:a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, doseresponse clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-923.

• 30) Nishimura T, Shimizu T, Mineo I, et al. Influence of daily drinking habits on ethanol-induced hyperuricemia. Metabolism 1994;43:745-748.
  pubmed

• 31) Rodnan GP. The pathogenesis of aldermanic gout:procataretic role of fluctuation in serum urate concentration in gouty arthritis provoked by yeast and alcohol, Clin Res 1980;28:359A.

• 32) Kanabrocki EL, Third JL, Ryan MD, et al. Circadian relationship of serum uric acid and nitric oxide. JAMA 2000;283:2240-2241.
  pubmed

• 33) http://www.ganko.tohoku.ac.jp/seminar/h16-abst/0624-03,html

• 34) Fiechtner JJ, Simkin PA. Urate spherulites in gouty synovia. JAMA 1981;245:1533-1536.
  pubmed

• 35) Schuind FA, Remmelink M, Pasteels JL. Co-existent gout and septic arthritis at the wrist:a case report. Hand Surg 2003;8:107-109.

• 36) Ortiz-Bravo E, Sieck MS, Schumacher HR Jr. Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation, Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. Arthritis Rheum 1993;6:1274-1285.

• 37) Terkeltaub R, Smeltzer D, Curtiss LK, et al. Low density lipoprotein inhibits the physical interaction of phlogistic crystals and inflammatory cells. Arthritis Rheum 1986;29:363-370.
  pubmed

• 38) Kozin F, McCarty DJ. Molecular orientation of immunoglobulin G adsorbed to microcrystalline monosodium urate monohydrate. J Lab Clin Med 1980;95:49-58.
  pubmed

• 39) Gordon TP, Ahern MJ, Reid C, et al. Studies on the interaction of rheumatoid factor with monosodium urate crystals and case report of coexistent tophaceous gout and rheumatoid arthritis. Ann Rheum Dis 1985;44:384-389.
  pubmed

• 40) Bomalaski JS, Lluberas G, Schumacher HR Jr. Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum 1986:29:1480-1484.
  pubmed

• 41) Pascual E, Castellano JA. Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals. J Rheumatol 1992;19:600-603.

• 42) Pascual E, Jovani V. A quantitative study of the phagocytosis of urate crystals in the synovial fluid of asymptomatic joints of patients with gout. Br J Rheumatol 1995;34:724-726.
  pubmed

• 43) Pascual E. Gout update:from lab to the clinic and back. Curr Opin Rheumatol 2000;12:213-218.

• 44) Yagnik DR, Hillyer P, Marshall D, et al. Noninflammatory phagocytosis of monosodium urate monohydrate crystals by mouse macrophages. Implications for the control of joint inflalnmation in gout. Arthritis Rheum 2000 ;43:1779-1789.
  pubmed

• 45) Landis RC, Yagnik DR, Florey O, et al. Safe disposal of inflammatory monosodium urate monohydrate crystals by differentiated macrophages. Arthritis Rheum 2002;46:30263033.

• 46) Yagnik DR, Evans BJ, Florey O, et al. Macrophage release of transforming growth factor betal during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2004;50:2273-2280.

• 47) Liote F, Prudhommeaux F, Schiltz C, et al. Inhibition and prevention of monosodium urate monohydrate crystal-induced acute inflammation in vivo by transforming growth factor beta1. Arthritis Rheum 1996;39:1192-1198.
  pubmed

• 48) Schreiner O, Wandel E, Himmelsbach F, et al. Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure:an explanation for infrequent gout episodes in chronic renal failure patients?Nephrol Dial Transplant 2000;15:644-649.
  pubmed

• 49) Rivelis AL, Rivelis AC. Acute gout. In:Gout, hyperuricemia, and other crystal-associated arthropaties, In:Smyth CJ, Holers W, editors. New York:Marcel Dekker;1999:175.

• 50) 岡部英明. 全身性の多発性関節炎を呈した痛風の1例. 高尿酸血症と痛風2005;13:90-93.

P.30 掲載の参考文献

• 1) Grateau G. Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology 2004;43:410-415.
  pubmed

• 2) Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med 2001;345:1748-1757.
  pubmed

• 3) 岡田全司. 高IgD症候群. リウマチ病セミナーX (七川歡次監修). 1999, p 13-21, 大阪, 永井書店.

• 4) Prieur AM. A recently recognized chronic inflammatory disease of early onset characterized by the triad of rash, central nervous system involvement and arthropathy. Clin Exp Rheumatol 2001;19:103-106.

• 5) Aganne E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP 3/CIASI/PYPAF1 gene with abroad phenotype including recurrent fever, cold sensitivity, sensorineural daefness, and AA amyloidosis. Arthritis Rheum 2002;46:2445-2452.

• 6) Lindslay CB, Petty RE. Overview and report on international registory of sarcoid arthritis in children. Curr Rheumatol Rep 2000;2:343-348.

• 7) Ben-Chetrit E, Levy M. Familial mediterranean fever. Lancet 1998;351:659-664.
  pubmed

• 8) 浜井啓子, 三浦 亮. 家族性地中海熱. 日本臨床別冊1998;血液症候群III:496-498.

• 9) The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial mediterranean fever. Cell 1997;90:797-807.

• 10) The French FMF Consortium. A candidate gene for familial mediterranean fever:The French FMF Consortium. Nat Genet 1997;17:25-31.

• 11) Tomiyama N, Oshiro S, Higashiuesato Y, et al. End-stage renal disease associated with familial mediterranean fever. Intern Med 2002;41:221-224.
  pubmed

• 12) Shinozaki K, Agematsu K, Yasui K, et al. Familial mediterranean fever in 2 Japanese families. J Rheumatol 2002;29:1324-1325.
  pubmed

• 13) 篠崎康治, 南雲治夫, 池上みのり, ほか. 家族性地中海熱の4家系. 小児科臨床2003;56:325-329.

• 14) Yoshida K, Kanaoka S, Kajimura M, et al. A Japanese case of familial mediterranean fever with family history demonstrating a mutation in MEFV. Intern Med 2003;42:761-764.
  pubmed

• 15) Komatsu M, Takahashi T, Uemura N, et al. Familial mediterranean fever medicated with an herbal medicine in Japan. Pediatr Int 2004;46:81-84.
  pubmed

• 16) Kotone-Miyahara Y, Takaori-Kondo A, Fukunaga K, et al. E148Q/M694I mutation in 3 Japanese patient with familial mediterranean fever. Int J Hematol 2004;79:235-237.
  pubmed

• 17) Nakamura A, Yazaki M, Tokuda T, et al. A Japanese patient with familial mediterranean fever associated with compound heterozygosity for pyrin variant E148Q/M694I. Intern Med 2005;44:261-265.
  pubmed

• 18) Ben-Chetrit E, Backenroth R. Amylidosis induced end-stage renal disease in patients with familial mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis 2001;60:146-149.

• 19) Cazeneuve C, Ajrapetyan H, Papin S, et al. Identification of MEFV-independent modifying genetic factors for familial mediterranean fever. Am J Hum Genet 2000;67:1136-1143.
  pubmed

• 20) Ben-Chetrit E, Levy M. Colchicine prophylaxis in familial mediterranean fever:reappraisal after 15 years. Semin Arthritis Rheum 1991;20:241-246.
  pubmed

• 21) Sohar E, Gafni J, Pras M, et al. Familial mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967;43:227-253.
  pubmed

• 22) Touitou I. The spectrum of familial mediterranean fever (FMF) mutations. Eur J Hum Genet 2001;9:473-483.
  pubmed

• 23) Booth DR, Lachmann HJ, Gillmore JD, et al. Prevalence and significance of the familial mediterranean fever gene mutation encoding pyrin Q148. QJM 2001;94:527-531.
  pubmed

• 24) Livneh A, Langevitz P, Zemer, et al. Criteria for the diagnosis of familial mediterranean fever. Arthritis Rheum 1997;40:1879-1885.
  pubmed

• 25) Masson C, Simon V, Hoppe E, et al. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS):definition, semiology, prognosis, pathogenesis, treatment, and place relative to other periodic joint diseases. Joint Bone Spine 2004;71:284-290.
  pubmed

• 26) Williamson LM, Hull D, Mehta R, et al. Familial hibernian fever. Q J Med 1982;51:469-480.
  pubmed

• 27) McDermott MF, Aksentijevich I, Galin J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133-144.

• 28) Aganna E, Hammond L, Hawkins PN, et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 2003;48:2632-2644.
  pubmed

• 29) Kusuhara K, Nomura A, Nakao F, et al. Tumour necrosis factor receptor-associated periodic syndrome with anovel mutation in the TNFRSFIA gene in a Japanese family. Eur J Pediatr 2004;163:30-32.

• 30) Ida H, Kawasaki E, Miyashita T, et al. A novel mutation (T611) in the gene encoding tumour necrosis factor receptor superfamily 1 A (TNFRSFIA) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus. Rheumatology 2004;43:1292-1299.

• 31) Horiuchi T, Tsukamoto H, Mitoma H, et al. Novel mutations in TNFRSFIA in patients with typical tumor necrosis factor receptor-associated periodic syndrome and with systemic lupus erythematosus in Japanese. Int J Mol Med 2004;14:813-818.

• 32) Aksentijevich I, Galon J, Soares M, et al. The tumor-necrosis-factor receptor-associated periodic syndrome:new mutations in TNFRSFIA, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001;69:301-314.

• 33) Galon J, Aksentijevich I, McDermott MF, et al. TNFRSFIA mutations and autoinflammatory syndromes. Curr Opin Immunol 2000;12:479-486.

• 34) Drewe E, Huggins ML, Morgan AG, et al. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology 2004;43:1405-1408.
  pubmed

P.39 掲載の参考文献

• 1) Petty RE, Southwood TR Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis, Durban. J Rheumatol 1998;25:1991-1994.

• 2) 前田 晃. 若年性特発性関節炎2003:分類と治療. リウマチ病セミナーXV (七川歡次監修), 2004, p 19-27, 大阪, 永井書店.

• 3) Oen K Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis, Best Practice & Research Clinical Rheumatology 2002;16:347-360.
  pubmed

• 4) Minden K, Niewerth M, Listing J, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2392-2401.
  pubmed

• 5) Laaksonen A A prognostic study of juvenile rheumatoid arthritis:analysis of 544 cases. Acta Pediatr Scand 1966;166 (Suppl 1):23-30.

• 6) Calabro JJ, Marchesano JM, Farrino GR. Juvenile rheumatoid arthritis:long-term management and prognosis. J Musculoskeletal Med 1989;6:17-32.

• 7) Stillman JS, Barry PE. Juvenile rheumatoid arthritis. Arthritis Rheum 1977;20:171-175.
  pubmed

• 8) David J, Cooper C, Hickey J, et al. The functional and psychological outcome of juvenile chronic arthritis in young adulthood. Brit J Rheumatol 1994;33:876-881.

• 9) Anderson-Gare B, Faste A. The natural history of juvenile chronic arthritis:A cohort study. J Rheumatol 1995;22:308-314.

• 10) Flato B, Aamand A, Odd B, et al. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol 1998;25:366-375.

• 11) Koivuniemi R, Lerisalo-Repo M. Juvenile chronic arthritis in adulthood:A study of long-term outcomes in patients with juvenile chronic arthritis and adult rheumatoid arthritis. Clin Rheumatol 2000;39:198-204.

• 12) Zak M, Peckerson FR. Juvenile chronic arthritis into adulthood:A long-term follow-up study. Rheumatol 2000;39:198-204.

• 13) Oen K. Long-term outcomes and predictors of for patients with juvenile idiopathic arthritis. Best Practice & Research Clinical Rheumatology 2002;16:347-360.
  pubmed

• 14) Packman JC, Hell MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis. Rheumatol 2002;41:1428-1438.

• 15) Fantini F, Gerlone V, Gattinara, et al. Remision in juvenile chronic arthritis:a cohort study of 683 consecutive cases with a mean 10 years folowup. J Rheumatol 2003;30:539-584.

• 16) Flatto B, Lien G, Smerdel A, et al. Prognostic factors in juvenile rheumatoid arthritis:a case control study revealing early predictor and outcome after 14.4 years. J Rheumatol 2003;30:386-393.

• 17) Faster HE, Marshal N, Myers A, et al. Outcomes in adult with juvenile idiopathic arthritis:a quality of life study. Arthitis Rheum 2003;48:761-775.

• 18) Cabral DA, Petty RE, Malleson PN, et al. Visual prognosis in children with chronic anterior uveitis and arthritis. J Rheumatol 1994;21:2370-2375.
  pubmed

• 19) Cassidy JT, Sullivan DB, Petty RE, et al. Clinical patterns of chronic iridocyclitis in children with juvenile rheumatoid arthritis. Arthritis Rheum 1977;20:224-226.
  pubmed

• 20) Zulian F, Martini G, Falcini F, et al. Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis. J Rheumatol 2002;29:2446-2453.
  pubmed

• 21) Magni-Manzoni S, Pasir F, Pistorio A, et al. Prognostic factors for radiographic damage, and disability in juvenile idiopathic arthritis. Arhritis Rheum 2003;48:3509-3517.

• 22) van Rossum MS, Zwinderman HH, Boers M, et al. Radiologic features in juvenile idiopathic arthritis. Arthritis Rheuma 2003;48:507-515.

• 23) Doherty E, Rooney M, Coary R, et al. Health status of functionally independent young adult with chronic arthritis since childhood. J Orhtop Rheumat 1988;1:51-88.

• 24) Prieer AM, Chichville G. Prognostic factors in juvenile idiopathic arthritis. Current Rheumatology 2001;31:371-388.

• 25) Ravelli A, Martini A. Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp Rheumatol 2003;21 (Suppl 30):s81-93.

• 26) Ravelli A. Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. Clin Exp Rheumatol 2004:22:271-278.

• 27) Benedetti F, Meazza C, Vinerelli M, et al. Functional and prognostic relevance of the 173 polymorphism of macrophage migration inhibitory factor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003;48:1398-1407.

• 28) Murata N, Maeda A. The articular lesions and HLA in juvenile rheumatoid arthritis. Jap J Rheumatol 1994;5:29-39.

• 29) Masi L, Comaz R, Simonini G, et al. Association of low bone mass with vitamin D receptor gene and calcitonin receptor gene polymorphismsin in juvenile idiopathic arthritis. J Rheumatol 2002;29:2225-2231.

• 30) Peterson LS, MasonT, Nelson AM, et al. Psychosocial outcomes and health status of adult who had juvenile rheumatoid arthritis. Arch Rheumatol 1997;40:2235-2240.

• 31) Shanberg LE, Anthony KK, Gil KM, et al. Daily pain and symptoms in children with polyarticular arthritis. Arthritis Rheum 2003;48:1390-1397.

• 32) Miller JJ, Spity PW, Simpson U, et al. The social function of young adults who had arthritis in childhood. J Pediatr 1982;100:378-382.

• 33) Miller JJ. Psychosocial factors related to rheumatic disease in childhood. J Rheumatol 1993;26:1-11.

• 34) Ungerer JA, Horgan B, Chaitow J, et al. Psychosocial functioning in children and young adults with juvenile arthritis. Pediatrics 1988;81:195-202.

• 35) Billig AG, Moos RA, Miller JJ, et al. Psychosocial adaptation in juvenile rheumatic disease. Health Psychol 1987;6:345-359.

• 36) Timko C, Stovel KW, Moos RH, et al. A longitudinal study of risk and resistance factors among children with juvenile rheumatic disease. J Clin Child Psychol 1992;21:132-142.

• 37) Noll RB, Koziowski K, Gerhardt C, et al. Social, emotional, and behavioral functioning of children with juvenile rheumatoid arthritis. Arthritis Rheum 2000;43:1387-1396.

• 38) Shanberg LE, Anthony KK, Gil KM, et al. Daily pain and symptomes in children with polyarticular arthritis. Arthritis Rheum 2003;48:1390-1397.

• 39) Ostensen M, Almberg K, Koksvik HS. Sex, reproduction, and gynecological diaease in young adult with history of juvenile chronic arthritis. J Rheumatol 2000;27:1783-1377.

• 40) Ostensen M. Pregnancy in adult with history of juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:881-887.
  pubmed

• 41) 前田 晃, 村田紀和. 若年性関節リウマチの成人期に及んだ長期追跡調査. 平成11年大阪府特定疾患調査研究書. 平成12年3月, p42〜47, 骨関節難病部会.

• 42) Nelson JL, Ostensen M. Pregnancy and rheumatoid arthritis. Rheum Dis Clinic North America 1997;23:195-232.

• 43) Mujiej E, Kowakowski E, Ploski E. Pregnancy and early onset pauciarticular chronic arthritis. Ann Rheum Dis 1999;58:475-480.

• 44) Stoeker E. Prognosis in juvenile chronic arthritis:Folow-up of 433 chronic rheumatic children. Eur J Pediatr 1981;135:225-226.

• 45) French AR, Mason T, Nelson AM, et al. Increassed mortality in adullts with a history of juvenile rheumatoid arthritis:A population-based study. Arthritis Rheum 2001;44:523-527.

• 46) 前田 晃. 若年性関節リウマチの成人期におよんだ症例の妊娠, 出産, 育児の問題点. 平成14年大阪府特定疾患調査研究報告書. 平成15年3月,骨関節難病部会;印刷中.

• 47) 前田 晃, 村田紀和, 小松原良雄, ほか. 成人期に及んだ若年性関節リウマチの死因要因. 平成15年大阪府特定疾患調査報告書. 平成16年3月, 骨関節難病部会;印刷中.

• 48) Thomas E, Symmons EPM, Brewster DH, et al. National study of cell-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions;A 20 years follow up study. J Rheumatol 2003;30:958-965.

P.50 掲載の参考文献

• 1) Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-271.
  pubmed

• 2) Cantini F, Niccoli L, Storri L, et al, Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum 2004;33:294-301.
  pubmed

• 3) 橋本博史. 難治性血管炎の診療マニュアル. 厚生科学研究特定疾患対策研究事業. 2002, p13-18, 難治性血管炎に関する調査研究班.

• 4) Kobayashi S, Yano T, Matsumoto Y, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in japan:The first government-supported nationwide survey. Arthritis Rheum 2003 ;49:594-598.
  pubmed

• 5) Salvarani C, Crowson CS, O'Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted county, Minnesota, over a fifty-year period. Arthritis Rheum 2004;51:264-268.

• 6) Petursdottir V, Johansson H, Nordborg E, et al. The epidemiology of biopy-positive giant cell arteritis:special reference to cyclic fluctuations. Rheumatol 1999;38:1208-1212.

• 7) Duhaut P, Bosshard S, Calvet A, et al. Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses:a multicenter, prospective case-control study. J Rheumatol 1999;26:361-369.
  pubmed

• 8) Elling P, Olsson AT, Elling H. Synchronous variation of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark:association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996;23:112-119.
  pubmed

• 9) Alvarez-Lafuente R, Femandez-Gutierrez B, Jover JA, et al. Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis:analysis with quantitative real time polymerase chain reaction. Ann Rheum Dis 2005;64:780-782.

• 10) Powers JF, Bedri S, Hussein S, et al. High prevalence of herpes simplex virus DNA in temporal arteritis biopsy specimens. Am J Clin Pathol 2005;123:261-264.
  pubmed

• 11) Regan MJ, Wood BJ, Hsieh YH, et al. Temporal arteritis and chlamydia pneumoniae, failure to detect the organism by polymerase chain reaction in ninety cases and ninety controls. Arthritis Rheum 2002;46:1056-1060.
  pubmed

• 12) Weyand CM, Hicok KC, Hunder GG, et al. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen-binding site of the HLA-DR molecule. J Clin Invest 1992;90:2355-2361.

• 13) Jacobsen S, Baslund B, Madsen HO, et al. Mannose-binding lectin variant alleles and HLA-DR4 alleles are associated with giant cell arteritis. J Rheumatol 2002;29:2148-2153.
  pubmed

• 14) Boiardi L, Casali B, Nicoli D, et al. Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. J Rheumatol 2003;30:2160-2164.
  pubmed

• 15) Salvarani C, Casali B, Nicoli D, et al. Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. Arthritis Rheum 2003;48:3219-3223.
  pubmed

• 16) Weyand CM & Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999;42:844-853.
  pubmed

• 17) Nordborg C, Nordborg E, Petursdottir V, et al. Calcification of the internal elastic membrane in temporal arteries:Its relation to age and gender. Clin Exp Rheumatol 2001;19:565-568.

• 18) Cid MC, Hernandez-Rodriguez J, Esteban MJ, et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002;106:1664-1671.
  pubmed

• 19) Salvarani C, Cimino L, Macchioni P, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005;53:293-297.

• 20) Salvarani C & Hunder GG. GCA with low erythrocyte sedimentation rate:frequency of occurrence in a population-based study. Arthritis Rheum 2001;45:140-145.

• 21) Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis. Circulation 2003;107:2428-2434.
  pubmed

• 22) Romera-Villegas A, Vila-Coll R, Poca-Dias V, et al. The role of color duplex sonography in the diagnosis of giant cell arteritis. J Ultrasound Med 2004;23:1493-1498.
  pubmed

• 23) Evans JM, O'Fallon WM & Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. Ann Intern Med 1995;122:502-507.
  pubmed

• 24) Blockmans D, Stroobants S, Maes A, et al. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica:evidence for inflammation of the aortic arch. Am J Med 2000;108:246-249.
  pubmed

• 25) Taylor-Gjevre R, Vo M, Shukla D, et al. Temporal artery biopsy for giant cell arteritis. J Rheumatol 2005;32:1279-1282.
  pubmed

• 26) Diaz VA, DeBroff BM & Sinard J. Comparison of histopathologic features, clinical symptoms, and erythrocyte sedimentation rates in biopsy-positive temporal arteritis. Ophthalmology 2005;112:1293-1298.
  pubmed

• 27) Rodriguez-Pla A, Bosch-Gil JA, Rossello Urgell J, et al. Metalloproteinase-2 and-9 in giant cell arteritis:involvement in vascular remodeling. Circulation 2005;112:264-269.
  pubmed

• 28) Ma-Krupa W, Kwan M, Goronzy JJ, et al. Toll-like receptors in giant cell arteritis. Clin Immunol 2005;115:38-46.
  pubmed

• 29) Weyand CM & Goronzy JJ. Medium-and large-vessel vasculitis. N Engl J Med 2003;349:160-169.
  pubmed

• 30)Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis:Introduction. Arthritis Rheum 1990;33:1065-1067.
  pubmed

• 31) Jennette JC, Falk Rl, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-192.

• 32) Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis:duration and adverse outocomes. Arthritis Rheum 2003;49:703-708.

• 33) Weyand CM, Kaiser M, Yang H, et al. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002;46:457-466.
  pubmed

• 34) Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004;50:1332-1337.
  pubmed

• 35) Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-1318.
  pubmed

• 36) Bhatia A, Ell PJ & Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005;64:1099-1100.
  pubmed

• 37) Cantini F, Niccoli L, Salvarani C, et al. Treatment of longstanding active giant cell arteritis with infliximab:report of four cases. Arthritis Rheum 2001;44:2933-2935.
  pubmed

• 38) Andonopoulis AP, Meimaris N, Daoussis D, et al. Experience with inflixi mab (anti-TNFα monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003;62:116.

• 39) Tan AL, Holdsworth J, Pease C, et al. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003;62:373-374.
  pubmed

• 40) Seton M. Giant cell arterits in a patient taking etanercept and methotrexate. J Rheumatol 2004;31:1467.

骨関節, 脊椎, 神経

P.60 掲載の参考文献

• 1) 岩波康博, 藤木幸雄. 頸肩腕障害の診断と治療, 1993, 東京, 金原出版.

• 2) Chard MD, Hazelman R, Hazelman BL, et al. Shoulder disorders in the elderly:a community survey. Arthritis Rheum 1991;34:766-769.

• 3) van der Windt D, Koes BW, de Jong BA, et al. Shoulder disorders in general practice:incidence, patient characteristics and management. Ann Rheum Dis 1995;54:959-964.
  pubmed

• 4) Walker-Bone KE, Palmer Kr, Reading I, et al. Soft-tissue rheumatic disorders of the neck and upper limb:prevalence and risk factors, Semin Arthritis Rhem 2003;33:185-203.

• 5) Makela M, Heliovaara M, Sievers K, et al. Prevalence, determinants, and consequences of chronic neck pain in Finland. Am J Epidemiol 1991;134:1356-1367.
  pubmed

• 6) Cote P. The Saskatchewan health and back pain survey. Spine 1998;23:1689-1698.
  pubmed

• 7) Urwin M, Symmons D, Allison T, et al. Estimating the burden of musculoskeletal disorders in the community:the comparative prevalence of symptoms at different anatomical sites. Ann Rheum Dis 1998;57:649-655.
  pubmed

• 8) Westerling D, Jonsson BG. Pain from the neck-shoulder region and sick leave. Scand J Soc Med 1980;8:131-136.
  pubmed

• 9) Bovim G, Schrader H, Sand T. Neck pain in the general population. Spine 1994;12:1307-1309.
  pubmed

• 10) Rajala U, Keinanen-Kiukaanniemi S, Uusimaki A, et al. Musculoskeletal pains and depression in a middle-aged Finish population. Pain 1995;61:451-457.

• 11) Takala J, Sievers K, Klaukka T. Rheumatic symptoms in the middle-aged population in south-western Finland. Scand J Rheumatol 1982;47 (suppl):15-29.

• 12) Jacobsson L, Lindgarde F, Manthorpe R. The commonest rheumatic complaints of over six weeks' duration in a twelve month period in a defined Swedish population. Scand J Rheumatol 1989;18:353-360.

• 13) Lau EMC, Sham A, Wong KC. The prevalence of and risk factors for neck pain in Hong Kong Chinese. J Public Health Med 1996;18:396-399.

• 14) van der Donk J, Schouten JSAG, Passchier J, et al. The association of neck pain with radiological abnormalities of the cervical spine and personality traits in the general population. J Rheumatol 1991;18:1884-1889.

• 15) Andersson HI, Ejlertsson G, Leden I, et al. Chronic neck pain in a geographically defined general population:studies of differences in age, gender, social class and pain localization. Clin J pain 1993;9:174-182.

• 16) Romano JM, Turner JA. Chronic pain and depression:does the evidence support a relationship? Psychol Bull 1985;97:18-34.
  pubmed

• 17) Bergenudd H, Lindgarde F, Nilsson B, et al. Shoulder pain in middle age. Clin Orthop 1988;231:234-238.
  pubmed

• 18) Allander E. Prevalence, incidence and remission rates of some rheumatic diseases and syndromes. Scand J Rheumatol 1974;3:145-153.
  pubmed

• 19) Cunningham LSt Kelsey JL. Epidemiology of musculoskeletal impairments and their associated disability. Am J Public Health 1984;74:574-579.

• 20) Suka M, Yoshida K. Musculoskeletal pain in Japan:prevalence and interference with daily activities. Mod Rheumatol 2005;15:41-47.

• 21) 大田 寛. 関節症の有病率に関する調査研究. 日本整形外科学会雑誌1979;53:27-42.

• 22) Atroshi I, Gummesson C, Johnsson R, et al. Prevalence of carpal tunnel syndrome in the general population. JAMA 1999;282:153-158.
  pubmed

• 23) de Krom M, Knipschild PG, Kester ADM, et al. Carpal tunnel syndrome:prevalence in the general population. J Clin Epidemiol 1992;45:373-376.

• 24) Ferry S, Pritchard T, Keenan J, et al. Estimating the prevalence of delayed median nerve conduction in the general population. Br J Rheumatol 1998;37:630-635.
  pubmed

• 25) Makela M, Heliovaara M, Sievers K, et al. Musculoskeletal disorders as determinants of disability in Finns aged 30 years or more. J Clin Epidemiol 1993;46:549-559.

• 26) Brage S, Bjekedal T. Musculoskeletal pain and smoking in Norway. J Epidemiol Community Health 1996;50:166-169.

• 27) Palmer KT, Syddall H, Cooper C, et al. Smoking and musculoskeletal disorders:findings from a British national survey. Ann Rheum Dis 2003;62:33-36.
  pubmed

• 28) O'Dwyer KJ, Howie CR. Medial epicondylitis of the elbow. Int Orthop 1995;19:69-71.

• 29) Moore JS. Flexer tendon entrapment of the digits (trigger finger and trigger thumb), J Occup Environ Med 2000;42:526-545.

• 30) Strom T. Trigger finger in diabetes. J Med Soc N J 1977;74:951-954.

• 31) Dalton SE. The shoulder. In:Klippel JH, Dieppe P, editor. Rheumatology 2nd ed. London:Mosby International;1998:4.7.1-4.7.14.

• 32) Fauno P, Anderson HJ, Simonsen O. A long-term followup of the effect of repeated corticosteroid injections for stenosing tenosynovitis. J Hand Surg 1989;14A:242-243.

• 33) Schumacher HR, Dorwart BB, Korzeniowski OM. Occurrence of de Quervain's tendinitis during pregnancy. Arch Intern Med 1985;145:2083-2085.

• 34) Lam N, Thurston A. Association of obesity, gender, age and occupation with carpal tunnel syndrome. Aust NZJ Surg 1998;68:190-193.

• 35) de Krom M, Kester ADM, Knipschild PG, et al. Risk factors for carpal tunnel syndrome. Am J Epidemiol 1990;132:1102-1110.

• 36) Solomon DH, Katz JN, Bohn R, et al. Nonoccupational risk factors for carpal tunnel syndrome. J Gen Intern Med 1999;14:310-314.
  pubmed

• 37) Vessey MP, Villiard-Mackintosh L, Yeates D. Epidemiology of carpal tunnel syndrome in women of childbearing age:findings in a large cohort study. Int J Epidemiol 1990;19:655-659.

• 38) Hakim AJ, El Zayat S, Cherkas L, et al. The genetic contribution to carpal tunnel syndrome in women:at win study. Rheumatol 2001;40 (supp 1):133-133.

• 39) Potocki L, Chen KS, Koeuth T, et al. DNA rearrangements on both homologues of chromosome 17 in a mildly delayed individual with a family history of autosomal dominant carpal tunnel syndrome. Am J Hum Genetics 1999;64:471-478.

• 40) 小野雄一郎. 職業関連頸肩腕症候群. 日本災害医学会会誌1999;47:286-290.

• 41) 労働省安全衛牛部労働衛生課. 職場における頸肩腕症候群予防対策に関する報告書, 1995, 東京, 中央労働災害防止協会.

• 42) Bongers P, Kremer AM, ter Laak J. Are psychosocial factors risk factors for symptoms and signs of the shoulder, elbow or hand/wrist? A review of the epidemiological literature. Am J Ind Med 2002;41:315-342.
  pubmed

• 43) Harrington JM, Carter JT, Birrell L, et al. Surveillance case definitions for work-related upper limb pain syndromes. Occup Environ Med 1998;55:264-271.
  pubmed

• 44) Palmer K, Walker-Bone K, Linaker C, et al. The Southermpton examination schedule for the diagnosis of musculoskeletal disorders of the upper limb. Ann Rheum Dis 2000;59:5-11.
  pubmed

• 45) Walker-Bone K, Bying P, Linaker C, et al. Reliability of the Southermpton examination schedule for the diagnosis of upper limb disorders in the general population. Ann Rheum Dis 2002;61:1103-1106.

P.70 掲載の参考文献

• 1) Shane E, Papadopoulos A, Staron RB, et al. Bone loss and fracture after lung transplantation. Transplantation 1999;68:220-227.
  pubmed

• 2) Katsura H, Kida K A Comparison of bone mineral density in elderly female patients with COPD and bronchial asthma. Chest 2002;122:1949-1955.
  pubmed

• 3) Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003;114:10-14.
  pubmed

• 4) Massie RJ, Towns SJ, Bernard E, et al. The musculoskeletal complications of cystic fibrosis. J Paediatr Child Health 1998;34:467-470.
  pubmed

• 5) Attucci S, Maillot F, Degenne D, et al. Une polyarthrite rheumatoid declenchee par des surinfections d'une dilatation des bronches. Interet de I'antibiotherapie cyclique? Rev Pneumol Clin 2001;57:303-307.

• 6) De Coste SD, Imber MJ, Baden HP. Yellow nail syndrome. J Am Acad Dermatol 1990;22:608-611.
  pubmed

• 7) Mukhopafhyay A, Stanley NN. Churg-Strauss syndrome associated with montelukast. Postgrad Med J 2001; 77:390-391.
  pubmed

• 8) Schols AM. Pulmonary cachexia. Int J Cardiol 2002;85:101-110.
  pubmed

• 9) William W H, Clagett OT, et al. Articular manifestations in pulmonary diseases. JAMA 1954;155:1459-1463.

• 10) Howell DS. Hypertrophic osteoarthropathy, in Arthritis and Allied Conditions, 10th ed. In:DJ McCarty, editor. Philadelphia, , Lea & Febiger;1984:1195-1201.

• 11) Regan GM, Tagg B, Thomson ML, Subjective Assessment and objective measurement of finger clubbing. Lancet 1967;1:530-532.
  pubmed

• 12) Vazquez-Abad D, Pineda C, Martinez-Lavin. Digital clubbing:a numerical assessment of the deformity. J Rheumatol 1989;16:518-520.
  pubmed

• 13) Waring WW, Wilkinson RW, Wiebe RA, et al. Quantitation of digital clubbing in children. Am Rev Respir Dis 1971 ;104:166-174.
  pubmed

• 14) Baughman RP, Gunther KL, Buchsbaum JA, et al. Prevalence of digital clubbing in bronchogenic carcinoma by a new digital index. Clin Exp Rheumatol 1998;16:21-26.
  pubmed

• 15) Stridhar KS, Lobo C F, Altman RD, et al. Digital clubbing and lung cancer. Chest 1998;114:1535-1537.

• 16) Rassaw JW, Anderson G. Incidence of paramalignant disorders in bronchogenic carcinoma. Thorax 1975;30:86-90.

• 17) 平潟洋一, 北村 諭. ばち状指または肺性肥大性骨関節症を呈した原発性肺癌症例の臨床的検討.日胸疾会誌 1995;33:1080-1085.

• 18) Kelly P, Manning P, Cororan P, et al. Hypertrophic osteoarthropathy in association with pulmonary tuberculosis. Chest 1991 ;99:769-770.

• 19) Reeve PA, Harries AD, Nkhoma WA, et al. Clubbing in African patientg. with pulmonary tuberculosis. Thorax 1987;42:986-987.

• 20) Sly RM, Fuqua G, Matta EG, et al. Objective assessment of minimal digital clubbing in asthmatic children. Ann Allergy 1972;30:575-578.
  pubmed

• 21) Gilliland BC. Fibromyalgia, arthritis associated with systemic disease, and other arthritides, in Harrison's Principles of Internal Medicine, 16th ed. In:DL Kasper, et al, editors. New York, McGraw-Hill;2005:2055-2064.

• 22) West SG, Gilbreath RE, Lawless O. Painful clubbing and sarcoidosis. JAMA 1981;246:1338-1339.
  pubmed

• 23) Rahbar M, Sharma OP. Hypertrophic osteoarthropathy in sarcoidosis. Sarcoidosis 1990;7:125-127.
  pubmed

• 24) Hashmi S, Kaplan D. Asymmetric clubbing as a manifestation of sarcoid bone disease. Am J Med 1992;93:471.
  pubmed

• 25) Smither WJ. Secular changes in asbestosis in an asbestos factory. Ann NY Acad Sci 1965;132:166-181.

• 26) Coutts I I, Gilson JC, Kerr IH, et al. Significance of finger clubbing in asbestosis. Thorax 1987;42:117-119.
  pubmed

• 27) Galko B, Grossman RF, Day A, et al. Hypertrophic pulmonary osteoarthropathy in four patients with interstitial pulmonary diseases. Chest 1985;88:94-97.
  pubmed

• 28) Nakamura CT, Ng CY, Paton JY, et al. Correlation between digital clubbing and pulmonary function in cystic fibrosis. Pediatr Pulmonol 2002;33:332-338.

• 29) Botton E, Saraux A, Laselve H, et al. Musculoskeletal manifestations in cystic fibrosis. Joint Bone Spine 2003;70:327-335.
  pubmed

• 30) Evans W. Reversal of hypertrophic osteoarthropathy after chemotherapy for bronchogenic carcinoma, J Rheumatol 1980;7:93-97.
  pubmed

• 31) Sansores RH, Villalba-Caloca J, Ramirez-Venegas A, et al. Reversal of digital clubbing after lung transplantation. Chest 1995;107:283-285.
  pubmed

• 32) Augarten A, Goldman R, Laufer J, et al. Reversal of digital clubbing after lung transplantation in cystic fibrosis patients:a clue to the pathogenesis of clubbing. Pediatr Pulmonol 2002;34:378-380.

• 33) Martiez-Laivn M. Digital clubbing and hypertrophic osteoarthropathy:a unifying hypothesis. J Rheumatol 1987;14:6-7.

• 34) Flavell G. Reversal of pulmonary hypertrophic osteoarthropathy by vagotomy. Lancet 1956;1:260-262.

• 35) Dailey F, Genovese P, Behner R. Patent ductus arteriosus with reversal of flow in adults. Arch Intern Med 1962;56:865-882.

• 36) Maeda H, Kumagai K, Konishi F, et al. Successful treatment of arthralgia with tamoxifen citrate in a patient with pachydermoperiostosis. Rheumatology 2000;39:1158-1159.

• 37) Steiner H, Dahlback O, Walsestrom J. Ectopic growth-hormone production and osteoarthropathy in carcinoma of the bronchus. Lancet 1968;1:783-786.

• 38) Martiez-Laivn M, Castillejos G. Ferritin and prostaglandins in hypertrophic osteoarthropathy. J Rheumatol 1986; 13:834-836.

• 39) Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol 2004;203:721-728.
  pubmed

• 40) Vazquez-Abad D, M Martinez-Laivn M. Macrothrombocytes in the peripheral circulation of patients with cardiogenic hypertrophic osteoarthropathy. Clin Exp Rheumatol 1991;9:59-62.

• 41) Fox SB, Day CA Association between platelet Microthrombi and finger clubbing. Lancet 1991;338:313-314.
  pubmed

• 42) Trowbridge EA, Martin JF, Slater DN. Evidence for the theory of physical fragmentation of megakaryocytes, implying that all platelets are produced in the pulmonary circulation. Throm Res 1982;28:461-475.

• 43) Dickinson CJ, Martin JF. Megakaryocytes and Platelet clumps as the cause of finger clubbing. Lancet 1987;ii:1434-1435.

• 44) Olan F, Portela M, Navarro C, et al. Circulating vasculoar endothelial growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy. Correlation with disease activity. J Rheumatol 2004;31:614-616.

P.82 掲載の参考文献

• 1) Swinyard CA, Bleck EE. The etiology of arthrogryposis (Multiple Congenital Contracture). Clin Orthop 1985; 194:15-29.
  pubmed

• 2) Fisher RL, Johnstone WT, Fisher WH Jr, et al. Arthrogryposis multiplex congenita:a clinical investigation. J Pediatr 1970;76:255-261.
  pubmed

• 3) Hall JG. Arthrogryposis multiplex congenita:Etiology, Genetics, Classification, Diagnostic approach, and General aspects. J Pediatr Orthop (B) 1997;6:159-166.
  pubmed

• 4) Thompson GH, Bilenker RM. Comprehensive management of arthrogryposis multiplex congenita. Clin Orthop 1985;194:14.

• 5) Wynne-Davies R, Lloyd-Roberts G. Arthrogryposis multiplex congenita. Serch for prenatal factors in 66 sporadic cases. Arch Dis Child 1976;51:618-623.

• 6) Kurogi H, Inaba Y, Takahashi E, et al. Epizootic congenital arthrogryposis-hydranencephaly syndrome in cattle:Isolation of Akabane virus from affected fetuses. Arch Virol 1976;51:67-74.
  pubmed

• 7) Miura S, Hayashi T, Ishihara Y, et al. Neutralizing antibody to Akabane virus in precolosterol sera from calves with arthrogryposis-hydranencephaly syndrome. Brief report. Arch Gesamte Virusforsch 1974;46:377-380.

• 8) Hall JG, Genetic aspects of arthrogryposis. Clin Orthop 1985;194:44-53.
  pubmed

• 9) Franz G. Arthrogryposis multiplex congenita (Editorial). J Pediatr Orthop (B) 1997;6:157-158.

• 10) Murray C, Fixsen JA, Chir M. Management of knee deformity in classical arthrogryposis multiplex congenita (Amyoplasia congenita). J Pediatr Orthop (B) 1997;6:186-191.

• 11) Gibson DA, Urs NDK Arthrogryposis multiplex congenita. J Bone Joint Surg 1970;52-B:483-493.

• 12) Carlson WO, Speck GJ, Vicari V, et al. Arthrogryposis multiplex congenita:A long-term follow-up study. Clin Orthop 1985;194:115-123.
  pubmed

• 13) Drummond DS, MacKenzie DA. Scoliosis in arthrogryposis multiplex congenita. Spine 1978;3:146-151.
  pubmed

• 14) Huurman WW, Jacobsen ST. The hip in arthrogryposis multiplex congenita. Clin Orthop 1985;194:81-86.
  pubmed

• 15) Mead NG, Lithgow WC, Sweeney HJ. Arthrogryposis multiplex congenita. J Bone Joint Surg 1958;50-A:1285-1309.

• 16) Shapiro F, Bresnan MJ. Current concepts review. Orthopaedic management of childhood neuromuscular disease. J Bone Joint Surg 1982;64-A:949-953.

• 17) Clair HSS, Zimbler S. A plan of management and treatment results in the arthrogrypotic hip. Clin Orthop 1985;194:74-80.

• 18) Sodergard J, Ryoppy S. The knee in arthrogryposis. J Pediatr Orthop 1990;10:177-182.
  pubmed

• 19) Thomas B, Schopler S, Wood W, et al. The knee in arthrogryposis. Clin Orthop 1985;194:87-92.
  pubmed

• 20) Brunner R, Hefti F, Tgetgel JD. Arthrogrypotic joint contracture at knee and the foot:Correction with a circular frame. J Pediatr Orthop (B) 1997;6:192-197.

• 21) Vanpaemel L, Schoenmakers M, van Nesselrooij B, et al. Multiple congenital contractures. J Pediatr Orthop (B) 1997;6:172-178.
  pubmed

• 22) Guidera KJ, Drennan JC. Foot and ankle deformities in arthrogryposis multiplex congenita. Clin Orthop 1985;194:93-98.
  pubmed

• 23) Axt MW, Niethard FU, Doerlein L, et al. Principles of treatment of upper extremity in arthrogryposis multiplex congenita Type I. J Pediatr Orthop (B) 1997;6:179-185.

• 24) Palmer PM, MacEwen GD, Bowen JR, et al. Passive motion therapy for infants with arthrogryposis. Clin Orthop 1985;194:54-58.
  pubmed

• 25) Williams PF. Management of upper limb problems in arthrogryposis. Clin Orthop 1985;194:60-67.
  pubmed

P.97 掲載の参考文献

• 1) Griffiths HJ, Utz R, Burke J, et al. Adhesive capsulitis of the hip and ankle. AJR Am Roentgenol 1985; 144:101-105.
  pubmed

• 2) Brown MD, Gomez-Marin O, Brookfield KF, et al. Differential diagnosis of hip disease versus spine disease. Clin Orthop 2004;419:280-284.
  pubmed

• 3) Walsh G, Archibald CG. MRI in greater trochanter pain syndrome. Australas Radiol 2003;47:85-87.
  pubmed

• 4) Ozcakar L, Erol D, Kaymak B, et al. An underdiagnosed hip pathology:apropos of two cases with gluteus medius tendon tears. Clin Rheumatol 2004;23:464-466.

• 5) Magee T, Hinson G. Association of paralabral cyst with acetabular disorders. AJR Am Roentgenol 2000;174:1381-1384.
  pubmed

• 6) Tortolani PJ, Carbone JJ, Quartararo JG. Greater trochanteric pain syndrome in patients referred to orthopedic spine specialists. Spine J 2002;2:251-254.

• 7) Bewyer DC, Bewyer KJ. Rationale for treatment of hip abductor pain syndrome. Iowa Orthop J 2003;23:57-60.
  pubmed

• 8) 西林保朗. リウマチ性疾患の四肢痛. リウマチ科2002, 27(supple 1):151-161.

• 9) LaBan MM, Weir SK, Taylor RS. 'Bald trochanter' spontaneous rupture of the conjoined tendons of the gluteus medius and minimus presenting as a trochanteric bursitis. Am J Phys Med Rehabil 2004;83:806-809.
  pubmed

• 10) 西林保朗. 股関節周辺のbul-sitis. リウマチ病セミナーI (七川歡次監修). 1990, p136-156, 大阪, 永井書店.

• 11) Travell JG, Simons DG. Chapter7-16. Myofascial pain and dysfunction, The trigger point manual vol 2 The lower extremities 1992, p132-338.

• 12) Papadopoulos EC, Kahn SN. Piriformis syndrome and low back pain:a new classification and review of the literature. Orthop Clin North Am 2004;35:65-71.

• 13) Jager M , Wild A, Westhoff B, et al. Femoroacetabular impingement caused by femoral osseous head-neck bump deformity:clinical, radiological, and experimental results. J Orthop Sci 2004;9:256-263.
  pubmed

• 14) Saw T, Villar R. Footballer's hip a report of six cases. J Bone Joint Surg Br 2004;86:655-658.

• 15) Wenger DE, Kendell KR, Miner MR, et al. Acetabular labral tears rarely occur in the absence of bony abnormalities. Clin Orthop 2004;426:145-150.
  pubmed

• 16) 西林保朗. メラルジアパレステティカ. 関節外科 1987;6:385-393.

• 17) 古川哲雄. Meralgia anterior. ヤヌスの顔-神経内科臨床ノート-. 1987, p219-220, 東京,科学評論社.

• 18) Szendroi M, Kollo K, Antal I, et al. Intraarticular osteoid osteoma:clinical features, imaging results, and comparison with extraarticular localization. J Rheumatol 2004;31:957-964.
  pubmed

• 19) Agar M. Broadbent A, Chye R. The management of malignant psoas syndrome:case reports and literature review. J Pain Symptom Manage 2004;28:282-293.
  pubmed

• 20) 横山良樹. 高田敏也, 槌田典平, ほか. Cimetidineが著効を示した関節周囲の石灰沈着症. 整・災外 1998; 41:87-91.

P.107 掲載の参考文献

• 1) Charcot JM, Marie P. Sur une forme particuliere d'atrophie musculaire progressive souvent familiale debutant par les pieds et les jambes et atteingnant plus tard les mains. Rev Med 1886;6:97-138.

• 2) Patel PI, Roa BB, Welcher AA, et al. The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A. Nat Genet 1992;1:159-165.
  pubmed

• 3) Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's diseasde. Clin Genet 1974;6:98-118.
  pubmed

• 4) Dyck PJ, Lambert EH. Lower motor and primary sensory neuron disease with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies. Arch Neurol 1968;18:603-618.
  pubmed

• 5) Dyck PJ, Lambert EH. Lower motor and primary sensoly neuron disease with peroneal muscular atrophy. II. Neurologic, genetic, and electrophysiologic findings in various neuronal degenerations. Arch Neurol 1968;18:619-625.

• 6) Thomas PK, Calne DB, Stewart G. Hereditary motor and sensory polyneuropathy (peroneal muscularatrophy). Ann Hum Genet 1974;38:111-153.

• 7) Garcia CA. A clinical review of Charcot-Marie-Tooth. Ann NY Acad Sci 1999;883:69-76.

• 8) 大西晃生. 遺伝性ニューロパチーの新しい分類. 神経内科 1999;51:487-494.

• 9) Schenone A, Nobbio L, Caponnetto C, et al. Correlation between PMP-22 messenger RNA expression and phenotype in hereditary neuropathy with liability to pressure palsies. Ann Neurol 1997;42:866-872.
  pubmed

• 10) Hayasaka K, Himoro M, Sato W, et al. Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P (0) gene. Nat Genet 1993;5:31-34.

• 11) Hayasaka K, Himoro M, Sawaishi Y, et al. De novo mutation of the myelin P (0) gene in Dejerine-Sottas disease (hereditary motor and sensory neuropathy type III). Nat Genet 1993;5:266-268.

• 12) De Jonghe P, Timmerman V, Ceuterick C, et al. The thr124-to-met mutation in peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain 1999;122:281-290.

• 13) Young P, Grote K, Kuhlenbaumer G, et al. Mutation analysis in Charcot-Marie-Tooth disease type 1:point mutation in the MPZ gene and GJB1 gene cause comparable phenotypic heterogeneity. J Neurol 2001;248:410-415.
  pubmed

• 14) Shy ME, Arroyo E, Sladky J, et al. Heterozygous PO knockout mice develop a peripheral neuropathy that resembles chronic inflammatory demyelinating polyneuropathy (CIDP). J Neuropathol Exp Neurol 1997;56:811-821.

• 15) Yan WX, Archelos JJ, Hartung HP, et al. PO protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:286-292.

• 16) Bergoffen J, Scherer SS, Wang S, et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993;262:2039-2042.

• 17) Nicholson G, Corbett A. Slowing of central conduction in X-linked Charcot-Marie-Tooth neuropathy shown by brain stem evoked responses. J Neurol Neurosurg Psychiatry 1996;61:43-46.

• 18) Paulson HL, Garbern JY, Hoban TF, et al. Transient central nervous system white matter abnormality in X-linked Charcot-Marie-Tooth disease. Ann Neurol 2002;52:429-434.

• 19) Dyck PJ, Swanson CJ, Low PA, et al. Predonisolone-responsive hereditary motor and sensory neuropathy. Mayo Clin Proc 1982;57:239-246.

• 20) Grandis M, Shy ME. Current therapy for Charcot-Marie-Tooth disease. Curr Treat Options Neurol 2005;7:23-31.
  pubmed

• 21) Young P, Suter U. Disease mechanisms and potential therapeutic strategies in Charcot-Marie-Tooth disease. Brain Res Rev 2001;36:213-221.
  pubmed

• 22) Roy DR, Al-Sayyad MJ. Complications of surgery of the foot and ankle in hereditary neurologic disorders. Clin Orthop 2001 ;391:181-187.
  pubmed

• 23) 鈴木良平. Charcot-Marie-Tooth病の足変形とその治療経験. 日本足の外科学会雑誌 1998;19:175-176.

P.116 掲載の参考文献

• 1) Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome:a working case definition. Ann Intern Med 1988;108:387-389.
  pubmed

• 2) 木谷照夫, 倉恒弘彦. 慢性疲労症候群. 日本内科学会雑誌 1992;81:573-582.

• 3) 上田素子. 慢性疲労症候群とストレスとの関連-患者のストレスとストレスコーピングに関する研究-. 関西福祉科学大学大学院福祉臨床学専攻修士課程精神医学研究演習修士論文集. 2003, p13-34.

• 4) Narita M, Nishigami N, Narita N, et al. Association between Serotonin Transporter Gene Polymomphis m and Chronic Fatigue Syndrome. Biochem Biophys Res Commun 2003;311 (2):264-266.

• 5) Demitrack MA, Dale JK, Straus SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991;73 (6):1224-1234.
  pubmed

• 6) 室 慶直, 倉恒弘彦. 日本人慢性疲労症候群思者における血清中抗DFS70抗体. アレルギーの臨床 2000; 20:826-830.

• 7) Tanaka S, Kuratsune H, Hidaka Y, et al. Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int J Mol Med 2003;12:225-230.
  pubmed

• 8) 倉恒弘彦, 近藤一博, 生田和良, ほか. 感染症の新しい展開-germ theoryを超えて-慢性疲労症候群 (CFS). 日本内科学会雑誌 2001;90 (12):2431-2437.

• 9) Kuratsune H, Yamaguti K, Takahashi M, et al. Acylcarnitine Deficiency in Chronic Fatigue Syndrome. Cline Infect Dis 1994;18:S62-67.

• 10) Yamaguti K, Kuratsune H, Watanabe Y, et al. Acylcarnitine Metabolism during fasting and refeeding. Biochem Biophys Res Commun 1996;225:740-746.
  pubmed

• 11) Kuratsune H, Yamaguti K, Lindh G, et al. Brain regions involved in fatigue sensation:reduced acetylcarnitine uptake into the brain. Neuroimage 2002;17 (3):1256-1265.
  pubmed

• 12) 倉恒弘彦. CFSにおける脳代謝異常. Progress in Medicine 2005;25 (5):1272-1278.
  Medical*Online

• 13) Inoue K, Yamazaki H, Manabe Y, et al. Transforming growth factor-beta activated during exercise in brain depresses spontaneous motor activity of animals. Relevance To central fatigue. Brain Res 1999;846 (2):145-153.
  pubmed

• 14) Dmemttre E, Bastide L, D:Haese A, et al. Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients. J Biol Chem 2002;277 (38):35746-35751.
  pubmed

• 15) Ikuta K, Yamada T, Simomura T, et al. Diagnostic evaluation for 2', 5'-oligoadenylate synthetase activities and antibodies against Epstein-Barr virus and Coxiella Burnetii in patients with chronic fatigue syndrome in Japan. Microbes Infect 2003;5 (12):1096-1102.

• 16) 片渕俊彦. ウイルス感染疲労モデルにおけるサイトカイン・神経伝達物質異常. Progress in Medicine 2005; 25(5):1320-1325.
  Medical*Online

燐・カルシウム代謝

P.124 掲載の参考文献

• 1) Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002;17:2094-2105.
  pubmed

• 2) Lawson DEM, Fraser DR, Kodicek E. Identification of 1, 25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 1971;230:228-230.

• 3) Holick MF, Schnoes HK, DeLuca HF, et al. Isolation and identification of 1, 25-dihydroxycholecalciferol, a metabolite of vitamin D active in intestine. Biochemistry 1971;10:2799-2804.
  pubmed

• 4) Sherrard DJ, Herez G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure:an evolving disorder. Kidney Int 1993;43:436-442.

• 5) Ward MK Feest TG, Ellis HA, et al. Osteomalacic dialysis osteodystrophy:Evidence for water-borne etiological agent, probably aluminum. Lancet 1978;1:841-845.
  pubmed

• 6) Parkinson IS, Feest TG, Ward MK, et al. Fracturing dialysis osteodystrophy and dialysis encephalopathy:an epidemiological survey. Lancet 1979;1:406-409.
  pubmed

• 7) Ott SM, Maloney NA, Coburn JW, et al. The prevalence of bone aluminum deposition in renal osteodystrophyand its relation to the response to calcitriol therapy. N Engl J Med 1982;307:709-714.

• 8) Goodman WG. Bone disease and aluminun:Pathogenic consideration. Am J Kidney Dis 1986;6:330-335.

• 9) Bricker NS, Klahr S, Lubowitz H, et al. The pathophysiology of renal insufficiency. On the functional transformations in the residual nephrons with advancing disease, Pediatr Clin North Am 1971;18:595-611.
  pubmed

• 10) Portale AA, Booth BE, Halloran BP, et al. Effect of dietary phosphorus on circulating concentrations of 1, 25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984;73:1580-1589.
  pubmed

• 11) Liach F. Secondary hyperparathyroidism in renal failure:the trade-off hypothesis revisited. Am J Kidney Dis 1995;25:663-679.

• 12) Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1, 25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436-1443.
  pubmed

• 13) Delmez JA, Tindira C, Grooms P, et al. Parathyroid hormone suppression by intravenous 1, 25-dihydroxyvitamin D:A role for increased sensitivity to calcium. J Clin Invest 1989;83:1349-1355.
  pubmed

• 14) Gogusev J, Duchambon P, Hory B, et al. Decreased expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51:328-336.
  pubmed

• 15) Yano S, Sugimoto T, Tsukamoto T, et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 2000;58:1980-1986.
  pubmed

• 16) Goodman WG, Veldhuis JD, Belin TR, et al. Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J Clin Endocrinol Metab 1998;83:2765-2772.
  pubmed

• 17) Brown A, ritter C, finch J, et al. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats:role of dietary phosphate. Kidney Int 1999;55:1284-1292.
  pubmed

• 18) Brown A, Zhong M, Finch J, et al. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 1996;270:F454-F460.

• 19) Canaff L, Hendy GN. Human calcium-sensing receptor gene:Vitamin D response elements in promoters P1 and P2 confertransscriptional responsiveness to 1, 25-dihydroxyvitamin D3. J Biol Chem 2002;277:30337-30350.
  pubmed

• 20) Slatopolsky E, Finch J, Denda M. Phosphorus restriction prevents parathyroid gland growth:high phosporus directly stimtulates PTH secretion in vitro. J Clin Invest 1996;97:2534-2540.

• 21) Tatsumi S, Segawa H, Morita K, et al. Molecular cloning and hormonal regulation of PiT-1 a sodium-dependent phosphate cotransporter from rat parathyroid glands. Endocrinology 1998;139:1692-1699.
  pubmed

• 22) Kilav R, Silver J, Naveh-Many T. A conserved cis-acting element in the parathyoid hormone 3'-untranslated region is sufficient for regulation of RNA stability by calcium and phosphate. J Biol Chem 2001;276:8727-8733.

• 23) Sera-Brown A, Silver J, Brewer G, et al. Identification of AUF1 as a parathyroid hormone mRNA 3'-untranslated region-binding protein that determines parathyroid hormone mRNA stability. J Biol Chem 2000;275:7424-7429.

• 24) Dusso A, Pavlopoulos T, Naumovich L, et al. p21WAFl and tranforming growth factor-α mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int 2001;59:855-865.

• 25) Arnold A, Brown MF, Urena P, et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary hyperplasia. J Clin Invest 1995;95:2047-2053.
  pubmed

• 26) Tahara H, Imanishi Y, Yamada T, et al. Rare somatic inactivation of the multiple endocrine neoplasia type 1 gene in secondary hyperparathyroidism of uremia. J Clin Endocrinol Metab 2000;85:4113-4117.
  pubmed

• 27) Imanishi Y, Tahara H, Palanisamy N, et al. Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol 2002;13:1490-1498.
  pubmed

• 28) Hosokawa Y, Pollak MR, Brown EM, et al. Mutational analysis of the extracellular Ca2+-sensing receptor gene in human parathyroid tumors. J Clin Endocrinol Metab 1995;80:3107-3111.
  pubmed

• 29) Brown SB, Brierly TT, Palanisamy N, et al. Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia. J Clin Endocrinol Metab 2000;85:868-872.

• 30) Yano S, Sugilnoto T, Kanzawa M, et al. Association of polymorphic alleles of the calcium-sensing receptor gene with parathyroid hormone secretion in hemodialysis patients. Nephron 2000;85:317-323.
  pubmed

• 31) Nagaba Y, Heishi M, Tazawa H, et al. Vitamin D receptor gene polymorphisms affect secondary hyperparathyroidism in hemodialyzed patients. Am J kidney Dis 1998;32:464-469.
  pubmed

• 32) Pei Y, Herez G, Greenwood C, et al. Non-invasive prediction of aluminum bone disease in hemo-and peritoneal dialysis patients. Kidney Int 1992;41:1374-1382.

• 33) Galceran T, Martin KJ, Morrissey JJ, et al. Role of 1, 25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormone. Kidney Int 1987;32:801-807.
  pubmed

• 34) Picton ML, Moore PR, Maver EB, et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 2000;58:1440-1449.

• 35) Kazama JJ, Shigematsu T, Tsuda E, et al. Increased circulating levels of osteoclastogenesis inhibitory factor/osteoprotegerin in patients with chronic renal failure:possible roles in skeletal resistance to PTH in uremia. Am J Kidney Dis 2002;39:525-542.
  pubmed

• 36) Slatopolsky E, Finch J, Clay F, et al. A novel mechanism for skeletak resistance in uremia. Kidney Int 2000; 58:753-761.

• 37) Gejyo F, Yamada T, Odani S, et al. A new form of amyloid protein associated with hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun 1985;129:701-706.

• 38) 圓尾宗司:透析に関連して出現するリウマチ症状. リウマチ病セミナーXI (七川歡次監修) , 2000, p66-75, 大阪, 永井書店.

• 39) Chertow GM, Burke SK, Dillon MA, et al. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 1999;14:2907-2914.
  pubmed

• 40) Chertow GM, Burke SK, Raggi P, et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
  pubmed

• 41) Slatopolsky E, Weerts C, Thielan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1, 25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984;74:2136-2143.
  pubmed

• 42) Tsukamoto Y, Hanaoka M, Matsuo T, et al. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe hyperparathyroidism. Am J kidney Dis 2000;35:458-464.

• 43) Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMGO73 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003;63:248-254.
  pubmed

• 44) Block GA, Martin KJ, deFrancisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-1525.

• 45) Yano S, Sugirnoto T, Tsukamoto T, et al. Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism:possible usefulness of preoperative determination of parathyroid hormone level for prediction of bone region. Horm Metab Res 2003;35 (4):259-264.

• 46) Kitaoka M, Fukagawa M, Ogata E, et al. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int 1994;46:1110-1117.
  pubmed

• 47) Shiizaki K, Hatamura I, Negi S, et al. Percutaneous maxacalcitriol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int 2003;64:992-1003.
  pubmed

• 48) K/DOQI clinical practice guideline for Bone Metabolism and Disease in Chronic Kidney Disease. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2003;42 (suppl 3):S1-S147.

• 49) K/DOQI clinical practice guidelines for chronic kidney disease. Evaluation, classification, and stratification. Am J Kidney Dis 2002;39 (Suppl 1):S1-S245.

検査法

P.136 掲載の参考文献

• 1) Rubaltelli L, Fiocco U, Cozzi L, et al. Prospective sonographic and arthroscopic evaluation of proliferative knee joint synovitis. J Ultrasound Med 1994;13:855-862.
  pubmed

• 2) Kasukawa R, Takeda I, Iwadate H, et al. Ultrasonographic evaluation of synovial effusion and synovial proliferation pattern in the knee joints of patients with rheumatoid arthritis. Mod Rheumatol 2002;12:64-68.
  pubmed

• 3) 粕川禮司, 武田功, 菅野 孝. リウマチ科超音波検査アトラス. 2002, 大阪, 医薬ジャーナル社.

• 4) Walther H, Harms H, Krenn V, et al. Correlation of power Doppler sonography with vascularity of the synovial tissue of the knee joint in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2001;44:331-338.

• 5) Hau M, Kneitz C, Tony H-P, et al. High resolution ultrasound detects a decrease in pannus vascularization of small finger joints in patients with rheumatoid arthritis receiving with soluble tumor necrosis factor α receptor (etanercept). Ann Rheum Dis 2002;61:55-58.

• 6) Klauser A, Frauscher F, Schirmer M, et al. The value of conrtrast-enhanced color Doppler ultrasound in the detection of vascularization of finger joints in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:647-653.
  pubmed

• 7) Kasukawa R, Yamadera Y, Takahashi A, et al. Power Doppler sonography for detection of intraarticular vascularization in knee joints of patients with rheumatoid arthritis. Mod Rheumatol 2004;14:149-153.
  pubmed

• 8) Backhaus M, Burmester G-R, Gerber T, et al. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 2001;60:641-649.
  pubmed

• 9) Kasukawa R, Takahashi A, Yamadera Y, et al. Two localization patterns of vascularity demonstrated by power Doppler sonography at the suprapatellar recess in knee joints of patients with rheumatoid arthritis:intracapsular and supracortical. Mod Rheumatol 2004;14:227-230.
  pubmed

• 10) Qvistgaard E, Roging H, Torp-Pederson S, et al. Quantitative ultrasonography in rheumatod arthritis:evaluation of inflammation by Doppler technique. Ann Rheum Dis 2001;60:690-693.

• 11) Sato A, Takahashi A, Yamadera Y, et al. Doppler sonographic analysis of synovial vascularization in knee joints of patients with rheumatoid arthritis:increased color flow-signals and reduced vascular resistance. Mod Rheumatol 2005;15:33-36.
  pubmed

• 12) Takahashi A, Sato A, Yamadera Y, et al. Doppler sonographic evaluation of effect of treatment with infliximab (Remicade) for rheumatoid arthritis. Mod Rheumatol 2005;15:37-40.
  pubmed

• 13) Ribbens C, Andre B, Marcelis S, et al. Rheumatoid hand joint synovitis:gray-scale and power Doppler US quantifications following anti-tumor necrosis factor-α treatment:pilot s tudy. Radiology 2003;229:562-569.

• 14) Taylor PC, Steuer A, Gruber J, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 2004;50:1107-1116.

• 15) Terslev L, Torp-Pedersen S, Qvistgaard E, et al. Effect of treatrnent with etanercept (Enbrel, TNFR:Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography. Ann Rheum Dis 2003;62:178-181.

P.143 掲載の参考文献

• 1) Recht MP, Kramer J, Marcelis S , et al. Abnormalities of articular cartilage in the knee;analysis of available MR techniques. Radiology 1993;187:473-478.
  pubmed

• 2) Lynch TCP. Crues III IV, Morgan FW , et al. Bone abnormalities of the knee;prevalence and significance at MR imaging. Radiology 1989;171:761-766.

• 3) McAlindon TEM, Watt I, McCrae E et al. Magnetic resonance imaging in osteoarthritis of the knee:correlation with radiographic and scintigraphic findings. Ann Rheum Dis 1991;50:14-19.

• 4) Zanetti M, Bruder E, Romero J, et al. Bone marrow edema pattern in osteoarthritic knees:correlation between MR imaging and histologic findings. Radiology 2000;215:835-840.
  pubmed

• 5) Peterfy CG. Imaging of the disease process. Curr Opin Rheumatol 2002;14:590-596.
  pubmed

• 6) Peterfy CG, Guermazi A, Zami S, et al. Whole-organ magnetic resonance imaging score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 2004;12:177-190.

• 7) Havdrup T, Hulth A, Telhag H , et al. The subchondral born in osteoarthritis and rheumatoid arthritis of the knee. A histological and microradiographical study. Acta Orthop Scand 1976;47:345-350.

• 8) Radin EL, Rose RM. Role of subchondral bone in the initiation and progression of cartilage darnage. Clin Orthop 1986;213:34-40.
  pubmed

• 9) Newberry WN, Zukosky DK, Haut RC. Subfracture insult to a knee joint causes alterations in the bone and in the functional stiffness of overlying cartilage. J Orthop Res 1997;15:450-455.
  pubmed

• 10) Watson PJ, Carpenter TA, Hall LD , et al. Cartilage swelling and loss in a spontaneous model of osteoarthritis visualized by magnetic resonance imaging. Osteoarthritis Cart 1996;4:197-207.

• 11) Li B, Aspden RM. Composition and mechanical properties of cancellous bone from the femoral head of patients with osteoporosis and osteoarthritis. J Bone Miner Res 1997;12:641-651.
  pubmed

• 12) Burr DB. Anatomy and physiology of the mineralized tissues:role in the pathogenesis of osteoarthrosis. Osteoarthritis Cartilage 2004;12 (Suppl A):S20-S30.

• 13) Dieppe P, Cushnaghan J, Young P, et al. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 1993:52:557-563.
  pubmed

• 14) Bjurholm A, Kreicberg A, Bordin E , et al. Substance P-and CGRP-immunoreactive nerves in bone. Peptides 1998;9:165-171.

• 15) Felson DT, Chaisson CE, Hill CL, et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med 2001;134:541-549.
  pubmed

• 16) Felson DT, Mclaughlin S, Goggins J, et al. Bone marrow edema (BME) and its relation to x-ray progression in knee osteoarthritis (OA). Arthritis Rheum 2003;46:S558.

• 17) 日本整形外科学会. 膝疾患治療成績判定基準評解 (日本膝関節研究会編). 1994, 東京, 金原出版株式会社.

教育

P.149 掲載の参考文献

• 1) Ropes MW, Bennett GA, Cobb S, et al. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958;9:175-176.
  pubmed

• 2) Arnett FC, Edworthy SM, Bloch DA, et al. The ARA 1987 revised criteria for the classification of Rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.

• 3) アメリカリウマチ協会編, 日本リウマチ協会訳. リウマチ入門第6版. 日本リウマチ協会;昭41年.

• 4) アメリカリウマチ協会編, 日本リウマチ協会訳. リウマチ入門第7版. 日本リウマチ協会;昭49年.

• 5) アメリカ関節炎財団編, 日本リウマチ学会訳. リウマチ入門第9版. 日本リウマチ学会;1990.

• 6) Doherty M, Woolf A, for the EULAR standing committee on Education and Training. Guidelines for rheumatology undergraduate core curriculum. Ann Rheum Dis 1999;58:133-135.
  pubmed

• 7) Doherty M, Lanyon P. Rheumatology:What should all doctors know. Ann Rheum Dis 2000;59:409-413.
  pubmed

• 8) Doherty M, Dacre J, Dieppe P, et al. The 'GALS' locomoter screen. Ann Rheum Dis 1992;51:1165-1169.

• 9) Amor B. What competence does a rheumatologist need?:An international perspective. Ann Rheum Dis 2000; 59:580-582.
  pubmed

生物学的反応

P.161 掲載の参考文献

• 1) 美馬 亨. COX-21nhibitor. リウマチ病セミナーIX (七川歡次監修). 1998, p147-154, 大阪, 永井書店.

• 2) 志水正敏. 消炎鎮痛剤の消炎鎮痛以外の効果. リウマチ病セミナーXIII (七川歡次監修). 2002, P154-161 , 大阪, 永井書店.

• 3) 安波礼子. COX-2 selective inhibitorの期待と現実. リウマチ病セミナー XIII (七川歡次監修). 2002, p141-146, 大阪, 永井書店.

• 4) Fitz Gerald G A. Coxibs and Cardio vascular Disease. N Engl J Med 2004 ;351:1709-1711.

• 5) Bresalier RS, Sander RS, Quan H, et al. Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N Engl J Med 2005;352:1092-1102.

• 6) Martel-Pelletier J, Jean-Pierre P, Hassan F. Cyclooxygenase-2 and Prostaglandins in Articular Tissues. Seminars in Arthritis and Rheumatism 2003;33 (3):155-167.

• 7) 鹿取 信. オータコイド標準薬理学第6版 (今井 正, 宮本英七, 編). 2003, p105-135, 医学書院.

• 8) 鹿取 信. COX-2阻害薬の作用機序と選択性. Pharma Medica 2004;22 (12):25-30.
  Medical*Online

• 9) Wissam HF, Yulan H, Qing WH, et al. Prostaglandin E2 Regulates the Level and Stability of Cyclooxygenase-2 mRNA through Activation of p38 Mitogen-activated Protein Kinase in Interleukin-1β-treated Human Synovial Fibroblasts. J Biol Chem 2001;276 (34):31720-31731.

• 10) Takayama K, Garcia-Cardena G, Sukhova GK, et al. Prostaglandin E2 suppresses chemokine production in human macrophages trough the EP4 receptor. J Biol Chem 2002;277 (46):44147-44154.

• 11) Noguchi K, Maeda M, Ruwanpura SM, et al. Prostaglandin E2 (PGE2) downregulates interleukin (IL)-1alpha-induced IL-6 production via EP2/EP4 subtypes of PGE2 receptors in human periodontal ligament cells. Oral Dis 2005;11 (3):157-162.
  pubmed

• 12) Yakar I, Melamed R, Shakhar G, et al. Prostaglandin e (2) suppresses NK activity in vivo and promotes postoperative ttlmor metastasis in rats. Ann Surg Oncol 2003;10 (4):469-479.
  pubmed

• 13) 佐野 統. NSAIDs-COX-2インヒビターの最近の話題. 臨床リウマチ2003;15:193-206.

• 14) Jun Z, Jerry M Gilles, Kurt Barnhart, et al. A comparison of Medical Management with Misoprostol and Surgical Management for Early Pregnancy Failure. N Engl J Med 2005;353 (8):761-769.

• 15) Power I. Aspirin-induced asthma. Br J Anaesth 1993;71 (5):619-621.
  pubmed

• 16) Rocca B, Spain LM, Pure E. et al. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest 1999;103 (10):1469-1477.

• 17) Talosi G, Katona M, Racz K, et al. Prostaglandin E2 treatment in patent ductus arteriosus dependent congenital heart defects. J Perinat Med 2004;32 (4):368-374.

• 18) Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-3410.
  pubmed

• 19) Cantaro S, Milan MS, Marcon R, et al. Urinary excretion of vasoactive substances in chronic renal failure. Clin Nephrol 2001;55 (5):393-399.

• 20) Sano H, Hla T, Maier JAM, et al. In Vivo Cyclooxygenase Expression in Synovial Tissues of Patients with Rheumatoid Arthritis and Osteoarthritis and Rats with Adjuvant and Streptococcal Cell Wall Arthritis. J Clin Invest 1992;89:97-108.

• 21) Anderson GD, Hauser SD, McGarity KL, et al. Selective Inhibition of Cyclooxygenase (COX)-2 Reverses Inflammation Expression of COX-2 and Interleukin 6 in Rat Adjuvant Athritis. J Clin Invest 1996;97 (11):2672-2679.

• 22) O'Dell JR. Therapeutic Strategies for Rheumatoid Arthritis. N Engl J Med 2004;350:2591-2602.
  pubmed

• 23) Holmes SG, Still K, Buttle DJ, et al. Chemically modified teracyclines act through multiple mechanisms directly on osteoclast precursors. Bone 2004;35 (2):471-478.
  pubmed

• 24) Patel RN, Attur MG, Dave MN, et al. A Novel Medchanism of Action of Chelnically Modified Tetracyclines:Inhibition of COX-2-Mediated Prostaglandin E2 production. J Immunol 1999;3459-3467.
  pubmed

• 25) Take I, Kobayashi Y, Yamamoto Y, et al. Prostaglandin E2 strongly inhibits human osteoclast formation. Endocrinology 2005 Sep 8 [Epub ahead of print].

• 26) Pichiule P, Chavez JC, LaManna JC. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J Biol Chem 2004;279 (13):12171-12180.
  pubmed

• 27) Lader CS, Flanagan AM. Prostaglandin E2, Interleukin 1α, and Tumor Necrosis Factor-α Increase Human Osteoclast Formation and Bone Resorption in vitro. Endocrinology 1998;139:3157-3164.

• 28) Udagawa N, Kotake S, Kamatani N, et al. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 2002;4:281-289.
  pubmed

• 29) Tontonoz P, Hu E, Graves RA, et al. mPPAR gamma 2:tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8 (10):1224-1234.
  pubmed

• 30) Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferators-activated receptor gamma (PPAR gamma). J Biol Chem 1995;270 (22):12953-12956.

• 31) Jiang C, Ting At, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391 (6662):82-86.
  pubmed

• 32) Tsubouchi Y, Kawahito Y, Kohno M, et al. Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-Delta (12, 14)-prostaglandin J2. Biochem Biophys Res Commun 2001;283 (4):750-755.
  pubmed

• 33) 川人 豊. PPAR-γリガンドによる関節炎治療. リウマチ病セミナーXIV (七川歡次監修). 2003, p 161-173, 大阪, 永井書店.

• 34) Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I (kappa) B kinase-beta. Nature 1998;396 (6706):77-80.
  pubmed

• 35) Yamamoto Y, Yin MJ, Lin KM, et al. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 1999;274 (38):27307-27314.
  pubmed

• 36) Notoya K, Jovanovic DV, Reboul P, et al. The Induction of Cell Death in Human Osteoarthritis Chondrocytesby Nitric Oxide Is Related to the Production of Prostaglandin E2 Via the Induction of Cyclooxygenase-2. The Journal of Immunology 2000;165:3402-3410.

• 37) Miwa M, Saura R, Hirata S, et al. Induction of apoptosis in bovine articular chondrocyte by prostaglandin E (2) through cAMP-dependent pathway. Osteoarthritis Cartilage 2000;8 (1):17-24.
  pubmed

• 38) 前出恵治:結合組織病における肺高血圧症. リウマチ病セミナーXVI (七川歡次監修). 2005, p1-9, 大阪, 永井書店.

• 39) Hughes-Fulford M, Lewis ML. Effects of microgravity on osteoblast growth activation. Exp Cell Res 1996;224 (1):103-109.
  pubmed

• 40) Kumei Y, Shimokawa H, Hara E, et al. Microgravity induces prostaglandin E2 and interleukin-6 production in normal rat osteoblasts:role in bone demineralization. J Biotechnol 1996;47 (2-3):313-324.
  pubmed

• 41) Hughes-Fulford M. Function of the cytoskeleton in gravisensing during spaceflight. Adv Space Res 2003;32 (8):1585-1593.
  pubmed

P.172 掲載の参考文献

• 1) 塩沢俊一. 4章T細胞. 膠原病学. 2005, p53-67, 東京, 丸善株式会社.

• 2) Sakaguchi N, Takahashi T, Hata H, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003;426:454-460.
  pubmed

• 3) Panayi GS. The pathogenesis of Rheumatoid arthritis and the development of therapeutic strategies for the clinical investigation of biologics. Agents Actions Suppl 1995;47:1-21.
  pubmed

• 4) Lemaitre B, Nicolas E, Michaut L, et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-983.

• 5) Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-397.
  pubmed

• 6) Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-376.
  pubmed

• 7) Kasho T, Akira S. Dendric-cell function in Toll-like receptor and MyD88-knockout mice. Trends Immunol 2001; 22:78-83.

• 8) Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptor in the pathogenesis of human disease. Nature Immunol 2004;10:975-979.

• 9) Picard D. Heat-schock protein90, a chaperone for folding and regulation. Cell Mol life Sci 2002;59:1640-1648.

• 10) Nollen EA, Morimoto RI. Chaperoning signaling pathway:molecular chaperone as stress-sensing heat schock proteins. J Cell Sci 2002;115:2809-2816.

• 11) Hayem G, De Bandt M, Palazzo E, et al. Anti-heat shock protein 70 kDa and 90 kDa antibodies in seruln of patients with rheumatoid arthritis. Ann Rheurn Dis 1999;58:291-296.
  pubmed

• 12) Sugita T, Tanaka S, Murakami T, et al. Immunosuppressive effects of the heat shock protein 90-binding antibiotic geldanamycin. Biocheln Mol Biol Int 1999:147:587-595.

• 13) Crabtree GR. Generic signals and specific outcomes:Signaling through Ca, calcieurin and NF-AT. Cell 1999; 96:611-614.

• 14) Allison AC. Immunosuppressive drugs:the first 50 years and a glance forward. Immunopharmacol 2000;47:63-83.

• 15) Matsuda S, Moriguchi T, Koyasu S, et al. T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A. J Biol Chem 1998;273:12378-12382.
  pubmed

• 16) Werlen G, Jacinto E, Xia Y, et al. Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2promoter in T lymphocytes. EMBO J 1998;17:3101-3111.

• 17) Matsuda S, Shibasaki F, Takehana K, et al. Two distinct action mechanisms of immunophilin-ligand complexes. for the blockade of T-cell activation. EMBO Rep 2000;1:428-434.
  pubmed

• 18) Magari K, Miyata S, Ohkubo Y, et al. Calcineurin inhibitors exert rapid reduction of inflamrnatory pain in rat adjuvant-induced arthritis. Br J Pharmacol 2003;139:927-934.
  pubmed

P.178 掲載の参考文献

• 1) Faggiotto A, Paoletti R. Do pleiotropic effects of statins beyond lipid alterations exist in vivo?What are they and how do they differ between statins?Curr Atheroscler Rep 2000;2:20-25.
  pubmed

• 2) Liao JK. Beyond lipid lowering:the role of statins in vascular protection. Int J Cardiol 2002;86:5-18.
  pubmed

• 3) Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins:implications for cardiovascular event reduction. JAMA 1998;279:1643-1650.
  pubmed

• 4) 山下静也. スタチン系製剤のpleiotropic effects. 現代医療2004;36:2488-2495.

• 5) Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 2004;363:892-894.
  pubmed

• 6) Wenke K, Meiser B, Thiery J, et al. Silnvastatin initiated early after heart transplantation. 8-year prospective experience, Circulation 2003;107:93-97.
  pubmed

• 7) Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109 (suppl III):III-39-III-43.

• 8) McCarey DW, Mclnnes IB, Madhok R, et al. Trial of atrovastatin in rheumatoid arthritis (TARA):double-blind, randolnized placebo-controlled trial. Lancet 2004;363:2015-2021.

• 9) Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis. A population-based cohort study. Arthritis Rheum 2005;52:402-411.
  pubmed

• 10) 大川 寛, 七川歡次, 前田 晃. 慢性関節リウマチ患者の死因の変遷. 臨床リウマチ2001;13:94-101.

• 11) 前田恵治. 全身性エリテマトーデス, 抗リン脂質抗体症候群, RAと粥状硬化症. リウマチ病セミナーXV (七川歡次監修), 2003, p 16-23, 大阪,永井書店.

• 12) Mclnnes IB, McCarey DW, Sattar N. Do Stain offer therapeutic potential in inflammatory arthritis? Ann Rheum Dis 2004;63:1535-1537.

• 13) Palinski W. Imlnunomodulation:anew role for statins?Nat Med 2000;6:1399-1402.

• 14) Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins s electively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-692.

P.189 掲載の参考文献

• 1) Shiozawa S, Shiozawa K, Fujita T. Morphologic observations in the early phase of the cartilage-pannus junction. Arthritis Rheum 1983;26:472-478.
  pubmed

• 2) Shiozawa S, Jasin HE, Ziff M. Absence of immunoglobulins in rheumatoid cartilage-pannus junctions. Arthritis Rheum 1980;23:816-821.
  pubmed

• 3) Shiozawa K, Shiozawa S, Shimizu S, et al. Fibronectin on the surface of articular cartilage in rheumatoid arthritis. Arthritis Rheum 1984;27:615-621.
  pubmed

• 4) Shiozawa S, Yoshihara R, Kuroki Y, et al. Pathogenic importance of fibronectin in the superficial region of articular cartilage as a local factor for the induction of pannus extension on rheumatoid articular cartilage. Ann Rheum Dis 1992;51:869-873.
  pubmed

• 5) Ishikawa H, Smiley JD, Ziff M. Electron microscopic demonstration of immunoglobulin deposition in rheumatoid cartilage. Arthritis Rheum 1975;18:563-576.
  pubmed

• 6) Shiozawa S, Ziff M. Immunoelectron microscopic demonstration of fibronectin in rheumatoid pannus and at the cartilage-pannus junction. Ann Rheum Dis 1983;42:254-263.
  pubmed

• 7) Hino K, Shiozawa S, Kuroki Y, et al. EDA-containing fibronectin is synthesized from rheumatoid synovial fibroblast-like cells. Arthritis Rheum 1995;38:678-683.
  pubmed

• 8) Hino K, Maeda T, Sekiguchi K, et al. Adherence of synovial cells on EDA-containing fibronectin. Arthritis Rheum 1996;39:1685-1692.
  pubmed

• 9) Shiozawa K, Hino K, Shiozawa S. Alternatively spliced EDA-containing fibronectin in synovial fluid as a predictor of rheumatoid joint destruction. Rheumatology 2001;40:739-742.
  pubmed

• 10) Olsen N, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-2179.
  pubmed

• 11) Shiozawa S, Tanaka Y, Fujita T, et al. Destructive arthritis without lymphocyte infiltration in H2-c-fos transgenic mice. J Immunol 1992;148:3100-3104.
  pubmed

• 12) Kawasaki H, Nakata Y, Suzuki G, et al. Increased c-Fos/activator protein-1 confers resistance against anergy induction on antigen-specific T cell. Int Immunol 1999;11:1873-1880.
  pubmed

• 13) Shiozawa S, Tokuhisa T. Contribution of synovial mesenchymal cells to the pathogenesis of rheumatoid arthritis. Semin Arthritis Rheum 1992;21:267-273.

• 14) Asahara H, Fujisawa K, Kobata T, et al. Direct evidence of high DNA binding activity of transaction factor AP1 in rheumatoid arthritis synovium. Arthritis Rheum 1997;40:912-918.

• 15) Shimizu K, Kawasaki T, Morisawa T, et al. Spontaneous and cytokine regulated c-fos gene expression in rheumatoid synovial cells:resistance to cytokine stimulation when the c-fos gene is overexpressed. Ann Rheum Dis 2000;59:636-640.

• 16) Kuroki Y, Shiozawa S, Yoshihara R, et al. The contribution of human c-fos DNA to cultured synovial cells:A transfection study. J Rheumatol 1993;20:422-428.

• 17) Kuroki Y, Shiozawa S, Sugimoto T, et al. Constitutive c-fos expression in osteoblastic MC3T3-E1 cells stimulates osteoclast maturation and osteoclastic bone resorption. Clin Exp Immunol 1994;95:536-539.
  pubmed

• 18) Miyauchi A, Kuroki Y, Fukase M, et al. Persistent expression of proto-oncogene c-fos stimulates osteoclast differentiation. Biochem Biophys Res Commun 1994;205:1547-1555.
  pubmed

• 19) Shiozawa S, Shimizu K, Tanaka K, et al. Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J Clin Invest 1997;99:1210-1216.

• 20) Hikasa M, Yamamoto E, Kawasaki H, et al. p21 is down-regulated in conjunction with up-regulation of c-Fos in the lymphocytes of rheumatoid arthritis patients. Biochem Biophys Res Commun 2003;304:143-147.
  pubmed

• 21) Kawasaki H, Komai K, Ouyang Z, et al. c-Fos/activator protein-1 transactivates wee 1 kinase at G1/S to inhibit premature mitosis in antigen-specific Th1 cells. EMBO J 2001;20:4618-4627.

• 22) Kawasaki H, Komai K, Nakamura M, et al. Human wee 1 kinase is directly transactivated by and increased in association with c-Fos/AP-1:rheumatoid synovial cells overexpressing these genes go into aberrant mitosis. Oncogene 2003;22:6839-6844.

• 23) Tsuchida K, Chaki H, Takakura T, et al. Design, Synthesis, and Biological Evaluation of New Cyclic Disulfide Decapeptides That Inhibit the Binding of AP-1 to DNA. J Med Chem 2004;47 (17):4239-4246.

• 24) Adachi M, Watanabe-Fukunaga R, Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of 1pr mice. Proc Natl Acad Sci USA 1993;90:1756-1760.

• 25) Takahashi T, Tanabe M, Brannan CI, et al. Geralized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-976.

• 26) Shiozawa S, Hayashi S, Tsukamoto Y, et al. Identification of the gene loci that predispose to rheumatoid arthritis. Int Immunol 1998;10:1891-1895.
  pubmed

• 27) Shiozawa S, Hashiramoto A, Kawasaki H, et al. Variant of death receptor 3 (DR3) gene encoding molecule lacking death domain inhibits apoptosis and predisposes to progressive joint destruction in rheumatoid arthritis, submitted.

P.196 掲載の参考文献

• 1) Borkham-Kamphorst E, Stoll D, Gressner AM, et al. Inhibitory effect of soluble PDGF-b receptor in culture-activated hepatic stellate cells. Biochem Biophys Res Commun 2004;317:451-462.
  pubmed

• 2) Galli A, Crabb DW, Ceni E, et al. Antidiabetic thiazolidinediones inhibits collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002;122:1924-1940.
  pubmed

• 3) Qi Z, Atsuchi N, Ooshima A, et al. Blockade of type β transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 1999;96:2345-2349.

• 4) George J, Roulot D, Koteliansky VE, et al. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor:A potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999;96:12719-12724.

• 5) Nakao A, Fujii M, Matsumura R, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999;104:5-11.
  pubmed

• 6) Dooley S, Hamzavi J, Breitkopf K, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003;125:178-191.
  pubmed

• 7) Ikejima K, Takei Y, Honda H, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002;122:1399-1410.
  pubmed

• 8) Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524.
  pubmed

• 9) Poynard T, McHutchinson J, Manns M, et al. Impact of pegylated interferon alpha-2a and ribavirin on liver fibrosis in patients with chrnic hepatitis C. Gastroenterology 2002;122:1303-1313.

• 10) Inagaki Y, Nemoto T, Kushida M, et al. Interferon α down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 2003;38:890-899.

• 11) Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type I receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-750.

• 12) Terui Y, Saito T, Watanabe H, et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stage of chronic hepatitis C. Hepatology 2002;36:1022.

• 13) Iimuro Y, Nishio T, Morimoto T, et al. Delivery of matrix metalloproteinase-1 attenuates established liveribrosis in the rat. Gastroenterology 2003;124:445-458.
  pubmed

• 14) Siller-Lopez F, Sandoval A, Salgado S, et al. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis Gastroenterology 2004:126:1122-1133.
  pubmed

• 15) Watanabe T, Niioka M, Hozawa S, et al. Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride. J Hepatol 2000;33:224-235.
  pubmed

• 16) Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver fibrosis in rats. Nature Med 1999;5:226-230.
  pubmed

• 17) Janoschek N, van de Leur E, Gressner AM, et al. Induction of cell death in activated hepatic stellate cells by targeted gene expression of the thymidine kinase/ganciclovir system. Biochem Biophys Res Commun 2004; 316:1107-1115.
  pubmed

• 18) Inagaki Y, Kushida M, Higashi K, et al. Cell type-specific intervention of TGF-β/Smad signaling suppresses collagen gene expression and hepatic fibrosis in mice. Gastroenterology 2005;129:259-268.

• 19) Higashi K, Inagaki Y, Suzuki N, et al. Y-box binding protein YB-1 mediates transcriptional repression of human α2 (I) collagen gene expression by interferon-γ. J Biol Chem 2003;278:5156-5162.

• 20) Higashi K, Inagaki Y, Fujimori K, et al. Interferon-γ interferes with transforming growth factor-β signaling through direct interaction of YB-1 with Smad3. J Biol Chem 2003;278:43470-43479.

P.207 掲載の参考文献

• 1) Hill PR. 2. The Biology of Cancer. Clinical Oncology 8th ed. In:Rubin P, editor. WB Saunders;2001:32-45.

• 2) Lamarque V, Monka C, Commare MC, et al. 17. Risk of malignancies in patients treated with Sandimmun for autoimmune diseases. Cancer in Transplantation. Prevantion and Treatment. In:Touraine JL, et al, editors. Kluwer Academic Publishers;1996:141-148.

• 3) Hoshida Y, Aozasa K Malignancies in organ transplant recipients. Pathology International 2004;54 (9):649-658.
  pubmed

• 4) American College of Rheumatology/Hotline (FDA Meeting March 2003:Update on the Safety of New Drugs for Rheumatoid Arthritis), 2003.

• 5) Symmons DPM, Silman AJ. Anti-tumor necrosis factor therapy and the risk of lymphoma in rheumatoid arthritis:No clear answer. Arthritis Rheum 2004;50 (6):1703-1706.
  pubmed

• 6) Moritomo H, Ueda T, Hiyama T, et al. The risk of cancer in rheumatoid patients in Japan. Scand J Rheumatol 1995;24:157-159.
  pubmed

• 7) 生島 香, 上田孝文 久川原郁夫, ほか. 慢性関節リウマチ患者における悪性腫瘍発症のリスク. 別冊整形外科1998;34:19-22.

• 8) 生島 香, 上田孝文, 久川原郁夫, ほか. 慢性関節リウマチ患者における悪性腫瘍発症-とくにメソトレキセートと悪性リンパ腫発生の関連について-. 臨床リウマチ1999;11:19-25.

• 9) Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis:The effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients. Arthritis Rheum 2004;50 (6):1740-1751.
  pubmed

• 10) Hoshida Y, Tomita Y, Zhiming D, et al. Lymphoproliferative disorders in autoimmune diseases in Japan:Analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer 2004;108(3):443-449.
  pubmed

治療と副作用

P.212 掲載の参考文献

• 1) 遠藤平仁, ほか. 消炎鎮痛剤の腎障害. 腎と透析2003;増刊号:359-362.

• 2) 山田明. リウマチ膠原病と薬剤性腎障害. 日本臨床免疫学会雑誌2002:255-262.

• 3) 酒井 紀. 「老人の薬物性腎障害」分科会研究報告. 厚生省特定疾患・進行性腎障害調査研究班 (班長 黒川清) 平成7年度研究業績. 1996, p63-67.

• 4) 大野岩男. NSAIDによる腎障害. クリニカ2004;31 (1):69-73.

• 5) Clive DM, Stoff JS. Renal syndrome associated with nonsteroidal anti-inflammatory drugs. New E J med 1984; 310 (9):563-572.

• 6) Abraham PA, Keane WF. Glomerular and interstitial desease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 1984;4:1-6.

• 7) Rossert J, Cohn JJ, Harrington JT. Drug-induced interstitial nephritis. Kidney Int 2001;60:804-817.

• 8) Radford Jr MG, Holley KE, Grande JP. Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 1996;276:466-469.

• 9) Eriksson L-O, Sturfelt G, Thysell H. Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med 1990;89:313-321.
  pubmed

• 10) Whelton A, Stout RL, Spilman PS, et al. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. Ann Intern Med 1990;112:568-576.
  pubmed

• 11) Sturmer T, Erb AE, Keller F, et al. Determinants of impaired renal function with use of nonsteroidal antiinflammatory drugs:The importance of half-life and other medications. Am J Med 2001;111:521-527.

• 12) Suzanne K, Swan MD. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med 2000;33:1-9.

• 13) Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001;110:33s-42s.
  pubmed

• 14) Galli G, Panzetta G. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?J Nephrol 2002;15:480-488.

• 15) Perazella MA, Tray K. Selective Cyclooxygenase-2 inhibitors:A pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001;111:64-67.
  pubmed

P.220 掲載の参考文献

• 1) Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis:Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-591.
  pubmed

• 2) Braun J, Brandt J, Listing J, et al. Two-year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-234.
  pubmed

• 3) Braun J, Baraliakos X, Brandt J, et al. Persistant clinical response to the anti-TNF alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 2005;44:670-676.

• 4) Davis JC Jr. Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Semin Arthritis Rheum 2004;34:668-677.

• 5) Van der Bosch F, Devinck M, Kruithof E, et al. A prospective long-term study of the efficacy and safety of infliximab in 107 patients with spondyloarthropathy. Arthritis Rheum 50 (Suppl):S611.

• 6) Baraliakos X, Brandt J, Listing J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7:R439-R444.
  pubmed

• 7) Davis JC, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (Etanercept) for treatment ankylosing spondylitis:A randomized, controlled trial. Arthritis Rheum 2003;48:3230-3236.
  pubmed

• 8) Calin A, Dikmans BAC, Emery P, et al. Outcomes of a multicentre randomized clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;36:1594-1600.

• 9) Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 2005;44:342-348.
  pubmed

• 10) Baraliakos X, Brandt J, Listing J, et al. Two-years follow up results of a double-blind placebo controlled trial of etanercept in active ankylosing spondylitis. Arthritis Rheum 50 (Suppl):S615.

• 11) Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis:results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-1236.
  pubmed

• 12) Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis:resultsof the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-1157.

• 13) Covelli M, Scioscia C, Iannone F, et al. Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis:immediate benefits are not maintained after discontinuation of infliximab. Clin Exp Rheumatol 2005;23:145-151.

• 14) Anandarajah AP, Ritchlin CT. Etanercept in psoriatic arthritis. Expert Opin Biol Ther 2003;3:169-177.
  pubmed

• 15) Marzo-Ortega H, McGonagle D, O' Connor P, et al. Efficacy of etanercept in the treatment of the entheseal pathlogy in resistant spondyloarthropathy. A clinical and magnetic resonance imaging study. Arthritis Rheum 2001 ;44:2112-2117.

• 16) Baraliakos X, Listing J, Rudwaleit M, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005;64:1462-1466.
  pubmed

• 17) Mease P, Kivitz A, Burch F, et al. Etanercept treatment of psoriatic arthritis:safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-2272.
  pubmed

• 18) Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab:evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-1136.
  pubmed

• 19) Rudwaleit M, Baraliakos X, Listing J, et al. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 2005;64:1305-1310.
  pubmed

P.226 掲載の参考文献

• 1) Giannini EH, Cassidy JT. Methotrexate in juvenile rheumatoid arthritis:do the benefits outweigh the risk? Drug Saf 1993;9:325-339.
  pubmed

• 2) Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 1995;22:1566-1569.
  pubmed

• 3) 横田俊平. 小児特発性関節炎の分類と治療戦略. 治療1999;81:766-772.

• 4) De Benedetti F, Massa M, Pignatti O, et al. Serum soluble interleukin 6(IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994;93:2114-2119.

• 5) Rooney M, David J, Symons J, et al. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995;34:454-460.

• 6) Harrington J, Kirk A, Newman S. Developmental issues in adolescence and the impact of rheumatic disease, In Adolescent Rheumatology. Isenberg DA and Miller JJ, editors. London:Martin Dunitz;2000:21-34.

• 7) Stephan JL, Zeller J, Hubert PH, et al. Macrophage activation syndrome and rheumatic disease in childhood:a report of four new cases. Clin Exp Rheumatol 1993;11:451-456.

• 8) Yokota S, Miyamae T, Imagawa T, et al. Inflammatory cytokines and systemic-onset juvenile idiopathic arthritis. Modern Rheumatol (in press).

• 9) Brewer EJ, Giannini EH, Kuzmina H, et al. Penicillamine and hydroxychloroquine in the treatment of severe juvenile arthritis:results of the USA-USSR double-blind placebo-controlled trial. N Engl J Med 1986;314:1269-1276.

• 10) 横田俊平, 森 雅亮. 若年性関節リウマチに対するDMARDs治療法の新展開-メトトレキサートを中心とするMAP療法の試み. 小児科1995;36:271-281.

• 11) Aihara Y, Imagawa T, Katakura S, et al. Methotrexate therapy for juvenile rheumatoid arthritis in Japan-surveillance with a questionnaire at seven main facilities. Jpn J Rheumatol 1999;9:229-237.

• 12) Maini RM, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-1563.

• 13) Lovell D, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile RA. N Engl J Med 2000; 342:763-769.

• 14) Yokota S. Interleukin-6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003;15:581-586.
  pubmed

• 15) Murakami M, Hibi M, Nakagawa N, et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993;260:1808-1810.
  pubmed

• 16) Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59 (Suppl 1):21-27.

P.235 掲載の参考文献

• 1) Schaible T. Long term safty of infliximab. Can J Gastroenterol 2000;Suppl C:29-32.

• 2) Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with inflixiamb, a tumor necrosis factor α neutralizing agent. N Engl J Med 2001;345(15):1098-1104.

• 3) Jacob CO, McDevitt HO. Tumor necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988; 331:356-358.
  pubmed

• 4) Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000;343:1594-1602.

• 5) St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. A randomized, Controlled trial. Arthritis Rheum 2004;50 (11):3432-3443.
  pubmed

• 6) Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with Infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after Infliximab withdrawal. Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52(1):27-35.
  pubmed

P.241 掲載の参考文献

• 1) Engh CA Jr, Claus AM, Hopper RH Jr, et al. Long-term results using the anatomic medullary locking hip prosthesis. Clin Orthop 2001;393:137-146.
  pubmed

• 2) Xenos JS, Callaghan JJ, Heekin RD, et al. The porous-coated anatomic hip prosthesis, inserted without cement. A prospective study with a minimum of ten years of follow-up. J Bone Joint Surg 1999;81-A:74-82.
  pubmed

• 3) Bobyn JD, Mortimer ES, Glassman AH, et al. Producing and avoiding stress shielding. Laboratory and clinical observations of noncemented total hip arthroplasty. Clin Orthop 1992;274:79-96.
  pubmed

• 4) Maloney WJ, Sychterz C, Bragdon C, et al. Skeletal response to well fixed femoral components inserted with and without cement. Clin Orthop 1996;333:15-26.
  pubmed

• 5) Yamaguchi K, Masuhara K, Yamasaki S, et al. Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty. Bone 2003;33:144-149.

• 6) Yamaguchi K, Masuhara K, Yamasaki S, et al. Effects of discontinuation as well as intervention of cyclic therapy with etidronate on bone remodeling after cementless total hip arthroplasty. Bone 2004;35:217-223.

• 7) 上好昭孝. 更年期後骨粗鬆症に対する新しい治療法. リウマチ病セミナーXIV (七川歡次監修). 2003, p184-193. 大阪, 永井書店.

• 8) 勝又 隆. 骨疾患とBisphosphonate. リウマチ病セミナーVII (七川歡次監修). 1996, p187-195, 大阪. 永井書店.

• 9) 名井 陽. がん骨転移のメカニズムとビスフォスフォネート. リウマチ病セミナーXV (七川歡次監修). 2004, p28-36, 大阪, 永井書店.

• 10) Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis:three years of blinded therapy followed by one year of open therapy. Am J Med 1993 ;95:557-567.
  pubmed

• 11) Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-1271.

• 12) Fogelman I, Herd RJM, Blake GM , et al. Cyclical etidronate therapy for prevention of postmenopausal bone loss:a 1-year open-label follow-up study. Calcif Tissue Int 2000;66:348-354.

• 13) Bagger YZ, Tanko LB, Alexandersen P, et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 2003;33:301-307.

• 14) Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate:An unrecognized problem in gastro intestinal torelability. Osteoporosis Int 1994;4:320-322.

• 15) Nishii T, Sugano N, Masuhara K, et al. Longitudinal evaluation of time related bone remodeling after cementless total hip arthroplasty. Clinical Orthop 1997;334:121-131.

• 16) Yamaguchi K, Masuhara K, Ohzono K, et al. Evaluation of periprosthetic bone remodeling after cementless total hip arthroplasty-The influence of extent of porous coating. J Bone Joint Surg 2000;82-A:1426-1431.
  pubmed

• 17) Massari L, Bagni B, Biscione R, et al. Periprosthetic bone density in uncemented femoral hip implants with proximal hydroxyapatite coating. Bull Hosp Jt Dis 1996;54:206-210.
  pubmed

• 18) Kiratli BJ, Chenovich MM, McBeath AA , et al. Measurement of bone mineral density by dual-energy X-ray absorptiometry in patients with the Wisconsin hip, an uncemented femoral stem. J Arthroplasty 1996;11:184-193.

• 19) Venesmaa PK, Kroger HPJ, Miettinen HJI, et al. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty:a prospective randomized study. J Bone Miner Res 2001;16:2126-2131.

P.246 掲載の参考文献

• 1) Lipsky JJ. Mycophenolate Mofetil. Lancet 1996;348:1357-1359.
  pubmed

• 2) Chan TM, Li FK, Tang CSO, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343:1156-1162.

• 3) Karim MY, Alba P, Cuadrado MJ, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 2002;41:876-882.
  pubmed

• 4) Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-980.
  pubmed

P.253 掲載の参考文献

• 1) Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology. 2003 update on the role of bisphosphonates and bone health issues in wolnen with breast cancer. J Clin Oncol 2003;21:4042-4057.

• 2) Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines:the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-3736.

• 3) Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy:clinical experience in non-small-cell lung cancer. Drug Saf 2004;27:1081-1092.
  pubmed

• 4) National Comprehensive Cancer Network. http://www.nccn.org

• 5) 永田 靖, 楠原和郎, 渋谷景子, ほか. 骨転移に対する放射線療法, 骨・関節・靭帯2004;17:409-415.

• 6) 骨転移治療ハンドブック. 厚生労働省研究班編, 2004, p80-81, 金原出版.

• 7) Fuchs B, Trousdale RT, Rock MG. Solitary bony metastasis from renal cell carcinoma:significance of surgical treatment. Clin Orthop Relat Res 2005;431:187-192.
  pubmed

• 8) Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000;141:4793-4796.
  pubmed

• 9) Coxon FP, Helfrich MH , Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival:inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000;15:1467-1476.
  pubmed

• 10) Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211-2221.
  pubmed

• 11) Lee MV, Fong EM , Singer FR , et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602-2608.
  pubmed

• 12) Kunzmann V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 1999; 340:737-738.
  pubmed

• 13) 勝又 隆. 骨疾患とBisphosphonate. リウマチ病セミナーVII (七川歡次監修). 1996, p187-195 , 大阪, 永井書店.

• 14) 名井 陽. がん骨転移のメカニズムとビスフォスフォネート. リウマチ病セミナーXV (七川歡次監修). 2005, p28-36, 大阪, 永井書店.

• 15) Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-1200.
  pubmed

• 16) Lipton A, Colombo-Berra A, Bukowski RM, et al. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 2004;10:6397S-6403S.
  pubmed

• 17) Saad F, Gleason DM , Murray R, et al. Zoledronic acid prostate cancer study group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-882.

• 18) Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors:a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621.
  pubmed

• 19) Perrone F, Di Maio M, Budillon A, et al. Targeted therapies and non-small cell lung cancer:methodological and conceptual challenge for clinical trials. Curr Opin Oncol 2005;17:123-129.
  pubmed

• 20) Ali SM, Harvey HA , Lipton A. Metastatic breast cancer:overview of treatment. Clin Orthop Relat Res 2003; 415:S132-S137.

• 21) Myoui A, Nishimura R, Yoneda T, et al. C-src tyrosin kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003;63:5028-5033.

• 22) Yoshioka K, Foletta V, Bernard O, et al. A role for LIM kinase in cancer invasion. Proc Natl Acad Sci U SA 2003;100:7247-7252.

手術

P.258 掲載の参考文献

• 1) 厚井 薫. セラミック型膝単顆関節置換術. 関節外来2003;22:363-367.

• 2) Rand JA, Ilstrup DM. Survivorship analysis of total knee arthroplasty:Cumulative rates of survival of 9, 200 total knee arthroplasties. J Bone Joint Surg 1991;73A:397-409.

• 3) Insall JN , Dorr LD, Scott RD. Rationale of the Knee Society clinical rating system. Clin Orthop 1989;248:13-14.
  pubmed

P.271 掲載の参考文献

• 1) Ehni G. The role of spine fusion:question 9. Spine 1981;6:308-310.

• 2) Rohlman A, Neller S, Bergmann G, et al. Effect of an internal fixator and a bone graft on intersegmental spinal motion and intradiscal pressure in the adjacent regions. Eur Spine J 2001;10:301-308.

• 3) Hambly MF, Wiltse LL, Schneidermann G, et al. The transition zone above a lumbosacral fusion. Spine 1998;23:1785-1792.

• 4) Penta M, Sandhu A, Fraser RD. Magnetic resonance imaging assessment of disc degeneration 10 years after ALIF. Spine 1995;20:743-747.

• 5) Grevitt MP, Gardner AD, Spilsbury J, et al. The Graf stabilization system:early results in 50 patients. Eur Spine J 1995 ;4:169-175.
  pubmed

• 6) Freudiger S, Dubois G, Lorrain M. Dynamic neutralization of the lumbar spine confirmed on a new lumbarspine simulator in vitro. Arch Orthop Trauma Surg 1999;119:127-132.

• 7) Stoll TM, Dubois G, Schwarzenbach O. The dynamic neutralization system for the spine:a multi-center studyof a novel non-fusion system. Eur Spine J 2002;11(Suppl 2):S170-S178.

• 8) Schmoelz W, Huber JF, Nydegger T, et al. Dynamic stabilization of the lumbar spine and its effects on adjacent segments. J Spinal Disord & Techniques 2003;16:418-423.

• 9) van Ooji A, Oner FC, Verbout AJ. Complications of artificial disc replacement:a report of 27 patients with the SB Charite disc. J Spinal Disord Tech 2003;16:369-383.

• 10) Fernstrom U. Arthroplasty with intercorporal endoprosthesis in herniated disc and in painful disc. Acta Chir Scand Suppl 1966;357:154-159.
  pubmed

• 11) MacKenzie AH. Steel ball arthroplasty of lumbar intervertebral discs:A preliminary report. J Bone Joint Surg (Br) 1972;54:766.

• 12) Ray CD. Lumbar interbody prosthesis. In:Brock M, Mayer HM, Weigel K, editors. The Artificial Disc. Berlin:Springer-Verlag;1991:53-67.

• 13) Bao QB, Yuan HA. New technologies in spine:nucleus replacement. Spine 2002;27:1245-1247.
  pubmed

• 14) Husson JL, Schaer N, Le Nihouannen JC, et al. Nucleoplasty during discectomy:concept and experimental study. Rachis 1997;9:145-152.

• 15) Korge A, Nydegger T, Polard JL, et al. A spiral implant as nucleus prosthesis in the lumbar spine. Eur Spine J 2002;11(Suppl 2):S149-S153.

• 16) Buttner-Janz K, Hochschuler SH, McAfee PC. The artificial disk. New York, Springer-Verlag;2001.

• 17) Marnay T. Lumbar disc replacement:7-10 year results with 7-10 year results with Pro-Disc. Eur Spine J 2002;11:S19.

• 18) LeHuec JC, Kiar T, Friesem T, et al. Shock absorption in lumbar disc prosthesis:a preliminary mechanical study. J Spinal Disord & Techniques 2003;16:346-351.

• 19) Cummins B, Robertson J, Gill S. Surgical experience with an implanted artificial cervical joint. J Neurosurg 1998;88:943-948.
  pubmed

• 20) DiAngelo DJ, Roberston JT, Metcalf NH, et al. Biomechanical testing of an artificial cervical joint and an anterior cervical plate. J Spinal Disord & Techniques 2003;15:314-323.

• 21) Goffin J, Casey A, Kehr P, et al. Preliminary clinical experience with the Bryan cervical disc prosthesis. Neurosurgery 2002;51:840-847.
  pubmed

• 22) McAfee PC, Cunningham B, Dmitriev A, et al. Cervical disc replacement-Porous coated motion prosthesis:a comparative biomechanical analysis showing the key role of the posterior longitudinal ligament. Spine 2003;28:S176-S185.
  pubmed

• 23) Klara PM, Ray CD. Artificial nucleus replacement:clinical experience. Spine 2002;27:1374-1377.
  pubmed

• 24) Bertagnoli R, Schonmayr R. Surgical and clinical results with the PDN prosthetic disc-nucleus device. Eur Spine J 2002;11(Suppl 2):S143-S148.

• 25) Shim CS, Lee SH, Park CW, et al. Partial disc replacement with the PDN prosthetic disc nucleus device:early clinical results. J Spinal Disord & Techniques 2003;16:324-330.

• 26) Jin D, Qu D, Zhao L, et al. Prosthetic disc nucleus (PDN) replacement for lumbar disc herniation. J Spinal Disord & Techniques 2003;16:331-337.

• 27) Bertagnoli R, Vazquez RJ. The anterolateral transpsoatic approach (ALPA):a new technique for implanting prosthetic disc-nucleus devices. J Spinal Disord & Techniques 2003;16:398-404.

• 28) Husson JL, Korge A, Polard JL, et al. A memory coiling spiral as nucleus pulposus prosthesis:concept, specifications, bench testing, and first clinical results. J Spinal Disord & Techniques 2003;16:405-411.

• 29) Zippel H. "Charite modular":conception, experience and results. In:Brock M, Mayer HM, Weigel K, editors. The Artificial Disc. Berlin:Springer-Verlag;1991:69-77.

• 30) Grifflith SL, Shelokov AP, Buttner-Janz K, et al. A multicenter retrospective study of the clinical results of the LINK SB Charite intervertebral prosthesis. The initial European experience. Spine 1994;19:1842-1849.

• 31) Cinotti G, David T, Postacchini F. Results of disc prosthesis after a minimum follow-up period of 2 years. Spine 1996;21:995-1000.
  pubmed

• 32) Lemaire JP, Skalli W, Lavaste F, et al. Intervertebral disc prosthesis. Results and prospects for the year 2000. Clin Orthop 1997;337:64-76.
  pubmed

• 33) Zeegers WS, Bohnen LM, Laaper M, et al. Artificial disc replacement with the modular type SB Charite III:2-year results in 50 prospectedly studied patients. Eur spine J 1999;8:210-217.
  pubmed

• 34) McAfee PC, Fedder IL, Saiedy S, et al. Experimental design of total disk replacement:experience with a prospective randomized study of the SB Charite. DSpine 2003;28:S153-S162.
  pubmed

• 35) McAfee PC, Fedder IL, Saiedy S, et al. SB Charite disk replacement:report of 60 prospective randomized cases in a United States center. J Spinal Disord & Techniques 2003;16:424-433.

• 36) Yukawa Y, Lenke LG, Tenhula J, et al. A comprehensive study of patients with surgically treated lumbar spinal stenosis with neurogenic claudication. J Bone Joint Surg (Am) 2002;84:1954-1959.

• 37) Fritzell P, Hagg O, Wessberg P, et al. 2001 Volvo Award winner in Clinical Studies:lumbar fusion versus nonsurgical treatment for chronic low back pain. A multicenter randomized controlled trial from the Swedish Lumbar Spine Study Group. Spine 2001;26:2521-2534.

• 38) Burkus JK, Heim SE, Gornet MF, et al. Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-cage lumbar tapered fusion device. J Spinal Disord & Techniques 2003;16:113-122.

• 39) Hochschuler SH, Ohnmeiss DD, Guyer RD, et al. Artificial disc:preliminary results of a prospective study in the United States. Eur Spine J 2002;11(Suppl 2):S106-s110.

• 40) Marnay T. Lumbar disc replacement:7-10 year results with ProDisc. Eur Spine J 2002;11:S19.

• 41) Mayer HM, Wiechert K, Korge A, et al. Minimally invasive total disc replacement:surgical technique and preliminary clinical results. Eur Spine J 2002;11(Suppl 2):S124-S130.

• 42) Bertagnoli R, Kumar S. Indications for full prosthetic disc arthroplasty:a correlation of clinical outcome against a variety of indications. Eur Spine J 11(Suppl 2):S131-S136.

• 43) Tropiano P, Huang RC, Girardi FP, et al. Lumbar disc replacement. Preliminary results with ProDisc II after a minimum follow-up period of 1 year. J Spinal Disord & Techniques 2003;16:362-368.

• 44) Zigler JE. Clinical results with ProDisc:European experience and U. S. Investigation Device Exemption Study. Spine 2003;28:S163-S166.
  pubmed

• 45) Zigler JE, Burd TA, Vialle EN, et al. Lumbar spine arthroplasty. Early results using the ProDisc II:a prospective randomized trial of arthroplasty versus fusion.

• 46) Delamarter RB, Fribourg DM, Kanim LE, et al. ProDisc artificial total lumbar disc replacement:introduction and early results from the United States clinical trial. Spine 2003;28:S167-S175.
  pubmed

• 47) Wigfield CC, Gill SS, Nelson RI, et al. The new Frenchay artificial cervical joint. Results from a two-year pilot study. Spine 2002;27:244 6-2452.

• 48) Bryan VE Jr. Cervical motion segment replacement. Eur Spine J 2002;11(Suppl 2):S92-S97.

• 49) McAfee PC, Cunningham BW, Devine J, et al. Classification of heterotopic ossification (HO) in artificial disk replacement. J Spinal Disord & Techniques 2003;16:384-389.